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(57) The present invention relates to the total syn-
thesis of saccharide structures contained in the capsular
polysaccharide of Streptococcus pneumoniae type 1, to
glycoconjugates containing said saccharide structures
obtained by total synthesis and to use of such glycocon-
jugates and pharmaceutical compositions thereof in the
immunization against diseases associated with bacteria
containing said saccharide structures in their capsular
polysaccharide, and more specifically associated with
Streptococcus pneumoniae.














Field of the invention
[0001] The present invention relates to the total synthesis of saccharide structures contained in the capsular polysac-
charide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total
synthesis and to use of such glycoconjugates and pharmaceutical composition thereof in the immunization against
diseases associated with bacteria, and more specifically against diseases associated with Streptococcus pneumoniae.
Background of the invention
[0002] Gram-positive encapsulated bacterium Streptococcus pneumoniae (pneumococcus) is a major cause of mor-
bidity and mortality worldwide. They colonize the upper respiratory tract and cause invasive pneumococcal diseases
such as meningitis, bacteremia and bactermic pneumonia, and non-invasive pneumococcal diseases including acute
otis media and pneumonia. These diseases are prevalent in young children, the elderly and immunocompromised
individuals of all ages. In developing countries Streptococcus pneumoniae related diseases cause an estimated 1.2
million deaths annually of young children.
[0003] Structurally, three distinguished layers can be seen on the bacterial surface: plasma membrane, cell wall and
capsule. The cell wall consists of a peptidoglycan backbone anchoring the cell wall polysaccharide (C-polysaccharide)
and the capsular polysaccharide (CPS). The C-polysaccharide is a structure common to all the pneumococcal serotypes,
whereas CPS is specific to each of the 90 know serotypes and is the main virulence factor.
[0004] Out of the 90 serotypes the most common and prevalent serotypes found in the world are shown in figure 1.
This distribution varies also based on geography and age difference. Thus, a vaccine comprising glycoconjugates
containing an immunogenic carrier and saccharide structures derived from the capsular polysaccharide of the most
common and prevalent Streptococcus pneumoniae serotypes would provide immunization against a high percentage
of the diseases caused by this class of Gram-positive bacteria.
[0005] Several poly-valent pneumococcal vaccines were manufactured up to present. The commercially available 23-
valent pneumococcal polysaccharide vaccine (PPV), contains purified capsular polysaccharide (CPS) antigens of 23
serotypes. However, this vaccine is not effective in the case of infants and young children. The currently marketed
pneumococcal conjugate vaccine (PCV), PCV-7 (PrevnarTM) contains saccharides of capsular antigens of serotype 4,
6B, 9V, 14, 18C, 19F and 23F individually conjugated to diphtheria CRM197 and is effective in infants.
[0006] The currently marketed vaccines are effective in North America and Europe for individuals of a particular age.
The manufacturing process for these vaccines is complex and results in a higher price. Therefore, the vaccine is unaf-
fordable in most developing countries. It is the object of the present invention to provide affordable synthetic saccharide
vaccines that contain most of the prevalent serotypes of the developing world.
[0007] Streptococcus pneumoniae type 1 (SP1) is one of the most prevalent S. pneumoniae serotypes. Streptococcus
pneumoniae type 1 capsular polysaccharide is a linear polymer having as a repeating unit: [→3)-α-2,4,6-trideoxy-4-
amino-D-GalNAc-(1→4)-α-D-GalAp-(1→3)-α-D-GalAp-(1→].
[0008] Synthetic saccharide structures derived from [→3)-α-2,4,6-trideoxy-4-amino-D-GalNAc-(1→4)-α-D-
GalAp-(1→3)-α-D-GalAp-(1→] trisaccharide repeating unit of Streptococcus pneumoniae type 1 capsular polysaccharide
were already reported. However, the method developed by Bundle (Chem. Eur. J. 2010, 16, 3476.) provides α-methoxy
saccharides, which are not suitable for conjugation to an immunogenic carrier. Moreover, the procedure described by
Codée is low yielding due to the side-reactions and requires additional steps for providing saccharides suitable for
conjugation (J. Org. Chem. 2011, 76, 1692.)
[0009] It is the objective of the present invention to provide an improved synthetic route to access saccharide structures
functionalized with a linker, said saccharide structures being derived from [→3)-α-2,4,6-trideoxy-4-amino-D-Gal-
NAc-(1→4)-α-D-GalAp-(1→3)-α-D-GalAp-(1→] trisaccharide repeating unit of Streptococcus pneumoniae type 1 cap-
sular polysaccharide. Said saccharide structures have the advantage of being functionalized with a linker thus, being
suitable to be conjugated to an immunogenic carrier. Therefore, it is an objective of the present invention to provide
glycoconjugates and pharmaceutical compositions containing said glycoconjugates for immunization against diseases
associated with bacteria containing in their capsular polysaccharide one of the following structures: α-2,4,6-trideoxy-4-
amino-D-GalNAc-(1→4)-α-D-GalAp-(1→3)-α-D-GalAp-; α-2,4,6-trideoxy-4-amino-D-GalNAc-(1→4)-α-D-GalAp; α-D-
GalAp-(1→3)-a-D-GalAp; α-D-GalAp; α-2,4,6-trideoxy-4-amino-D-GalNAc; α-D-GalAp-(1→3)-α-D-GalAp-(1→3)-α-
2,4,6-trideoxy-4-amino-D-GaINAc; α-D-GalAp-(1→3)-α-2,4,6-trideoxy-4-amino-D-GalNAc; α-D-GalAp-(1→3)-α-2,4,6-
trideoxy-4-amino-D-GalNAc-(1→4)-α-D-GalAp. The pharmaceutical compositions comprising the glycoconjugates of
the present invention are useful for immunization against diseases associated with bacteria, and especially associated
with Streptococcus pneumoniae, said diseases including pneumonia, meningitis, otitis media, bacteremia and acute
exacerbation of chronic bronchitis, sinusitis, arthritis and conjunctivitis













[0010] The objective of the present invention is solved by the teaching of the independent claims. Further advantageous
features, aspects and details of the invention are evident from the dependent claims, the description, the figures, and
the examples of the present application.
Description of the invention
Definitions
[0011] The term "linker" as used herein encompasses molecular fragments capable of connecting the reducing-end
monosaccharide of a saccharide with an immunogenic carrier or a solid support, optionally by binding to at least one
interconnecting molecule. Thus, the function of the linker per se or together with the interconnecting molecule is to
establish, keep and/or bridge a special distance between the reducing-end monosaccharide and an immunogenic carrier
or a solid support. More specifically, one extremity of the linker is connected to the oxygen atom of the reducing-end
monosaccharide and the other extremity is connected with the interconnecting molecule, or directly with the immunogenic
carrier or the solid support.
[0012] As used herein, the term "interconnecting molecule" refers to a bifunctional molecule containing functional
group X and functional group Y, wherein functional group X is capable of reacting with the terminal thiol group on the
linker A and the functional group Y is capable of binding to an immunogenic carrier or to a solid support. Figure 2 displays
examples of interconnecting molecules, but does not restrict the interconnecting molecules that can be used according
to the present invention to the examples displayed herein.
[0013] The term "adjuvant" as used herein refers to an immunological adjuvant i.e. a material used in a vaccine
composition that modifies or augments the effects of said vaccine by enhancing the immune response to a given antigen
contained in the vaccine without being antigenically related to it. For the person skilled in the art, classically recognized
examples of adjuvants include:
- mineral-containing compositions, including calcium salts and aluminum salts (or mixtures thereof). Calcium salts
include calcium phosphate. Aluminum salts include hydroxides, phosphates, sulfates, etc., with the salts taking any
suitable form (e.g. gel, crystalline, amorphous, etc.). Adsorption to these salts is preferred. The mineral containing
compositions may also be formulated as a particle of metal salt. The adjuvants known as aluminum hydroxide and
aluminum phosphate may be also used. The invention can use any of the "hydroxide" or "phosphate" adjuvants that
are in general use as adjuvants. The adjuvants known as "aluminium hydroxide" are typically aluminium oxyhydroxide
salts, which are usually at least partially crystalline. The adjuvants known as "aluminium phosphate" are typically
aluminium hydroxyphosphates, often also containing a small amount of sulfate (i. e. aluminium hydroxyphosphate
sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation
influence the degree of substitution of phosphate for hydroxyl in the salt. Mixtures of both an aluminium hydroxide
and an aluminium phosphate can be employed in the formulation according to the present invention;
- saponins, which are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark,
leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the Quillaia
saponaria Molina tree have been widely studied as adjuvants. Saponin can also be commercially obtained from
Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria oficianalis (soap root). Saponin
adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs.
Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these tech-
niques have been identified, including QS7, QS 17, QS 18, QS2 1, QH-A, QH-B and QH-C. Saponin formulations
may also comprise a sterol, such as cholesterol. Combinations of saponins and cholesterols can be used to form
unique particles called immunostimulating complexes (ISCOMs). ISCOMs generally include a phospholipid such
as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the
ISCOM includes one or more of QuilA, QHA & QHC;
- microparticles (i.e. a particle of -100nm to -150pm in diameter, more preferably - 200nm to -30pm in diameter, or
-500nm to -10pm in diameter) formed from materials that are biodegradable and non-toxic. Such non-toxic and
biodegradable materaila include but are not restricted to poly(α-hydroxy acid), polyhydroxybutyric acid, polyorthoe-
ster, polyanhydride, polycaprolactone;
- CD1d ligands, such as an α-glycosylceramide, phytosphingosine-containing α-glycosylceramides, OCH, KRN7000
[(2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)- 1,3,4-octadecanetriol], CRONY- 101, 3"-0- sul-
fo-galactosylceram ide;
- immunostimulatory oligonucleotides, such CpG motif containing ones (a dinucleotide sequence containing an un-
methylated cytosine residue linked by a phosphate bond to a guanosine residue), or Cpl motif containing ones (a
dinucleotide sequence containing cytosine linked to inosine), or a double-stranded RNA, or an oligonucleotide
containing a palindromic sequence, or an oligonucleotide containing a poly(dG) sequence. Immunostimulatory oli-













gonucleotides can include nucleotide modifications/analogs such as phosphorothioate modifications and can be
double-stranded or (except for RNA) single-stranded;
- compounds containing lipids linked to a phosphate-containing acyclic backbone, such as the TLR4 antagonist E5564;
- oil emulsions (eg. Freund’s adjuvant).
[0014] Theoretically, each molecule or substance that is able to favor or amplify a particular situation in the cascade
of immunological events, ultimately leading to a more pronounced immunological response, can be defined as an
adjuvant.
[0015] In principle, through the use of adjuvants in vaccine formulations, one can
- direct and optimize immune responses that are appropriate or desirable for the vaccine;
- enable mucosal delivery of vaccines, i.e., administration that results in contact of the vaccine with a mucosal surface
such as buccal or gastric or lung epithelium and the associated lymphoid tissue;
- promote cell-mediated immune responses;
- enhance the immunogenicity of weaker immunogens, such as highly purified or recombinant antigens;
- reduce the amount of antigen or the frequency of immunization required to provide protective immunity; and
- improve the efficacy of vaccines in individuals with reduced or weakened immune responses, such as newborns,
the aged, and immunocompromised vaccine recipients.
[0016] Although little is known about their mode of action, it is currently believed that adjuvants augment immune
responses by one of the following mechanisms:
- increasing the biological or immunologic half-life of antigens;
- improving antigen delivery to antigen-presenting cells (APCs), as well as antigen processing and presentation by
the APCs e.g., by enabling antigen to cross endosomal membranes into the cytosol after ingestion of antigen-
adjuvant complexes by APC;
- mimicking danger inducing signals from stressed or damaged cells which serve to initiate an immune response;
- inducing the production of immunomodulatory cytokines;
- biasing the immune response towards a specific subset of the immune system; and
- blocking the rapid dispersal of the antigen challenge.
[0017] Saccharides are known by the person skilled in the art as TI-2 (T cell independent-2) antigens and poor immu-
nogens. Therefore, to produce a saccharide-based vaccine, said saccharides are conjugated to an immunogenic carrier
to provide a glycoconjugate, which presents an increased immunogenicity in comparison with the saccharide. In this
context the term "immunogenic carrier" is defined as a structure, which is conjugated to the saccharide to form a glyco-
conjugate that presents an increased immunity in comparison with the saccharide per se. Thus, the conjugation of the
saccharides to the immunogenic carrier has as effect the stimulation of the immune response against said saccharide,
without inducing an immune response against the said immunogenic carrier.
[0018] Thus the present invention relates to saccharides of general formula (I):
wherein A is a linker;
[0019] M, N and P represent independently of each other one of the following sugar fragments:













wherein each moiety S1, S2, and S3 is not more than once present in the general formula (I), sugar fragment S1 cannot
be simultaneously bound to -O-A-SH and sugar fragment S2, sugar fragment S3 cannot be simultaneously bound to
-O-A-SH and sugar fragment S1 and sugar fragment S2 cannot be simultaneously bound to -O-A-SH and sugar fragment
S3, and n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
and pharmaceutically acceptable salts of these saccharides.
[0020] Preferably not more than one of n1, n2 and n3 is 0 or n1 = n2 = n3 = 1. Also saccharides of general formula
(I) are preferred which comprise the sugar S1. Thus it is preferred that general formula (I) represents the following sugars:
H-(S1)-(S2)-(S3)-O-A-SH, H-(S2)-(S3)-(S1)-O-A-SH, H-(S3)-(S1)-(S2)-O-A-SH, H-(S1)-(S2)-O-A-SH, H-(S2)-(S3)-O-A-
SH, H-(S3)-(S1)-O-A-SH, H-(S1)-O-A-SH, H-(S2)-O-A-SH and H-(S3)-O-A-SH and more preferred H-(S1)-(S2)-(S3)-O-
A-SH, H-(S2)-(S3)-(S1)-O-A-SH, H-(S3)-(S1)-(S2)-O-A-SH, H-(S1)-(S2)-O-A-SH, H-(S2)-(S3)-O-A-SH, H-(S3)-(S1)-O-
A-SH, and H-(S1)-O-A-SH. Also preferred are the disulfides of such sugars, namely H-(S1)-(S2)-(S3)-O-A-S-A-
O-(S3)-(S2)-(S1)-H, H-(S2)-(S3)-(S1)-O-A-S-A-O-(S1)-(S3)-(S2)-H, H-(S3)-(S1)-(S2)-O-A-S-A-O-(S2)-(S1)-(S3)-H,
H-(S1)-(S2)-O-A-S-A-O-(S2)-(S1)-H, H-(S2)-(S3)-O-A-S-A-O-(S3)-(S2)-H, H-(S3)-(S1)-O-A-S-A-O-(S1)-(S3)-H,
H-(S1)-O-A-S-A-O-(S1)-H, H-(S2)-O-A-S-A-O-(S2)-H, and H-(S3)-O-A-S-A-O-(S3)-H. More preferred are
H-(S1)-(S2)-(S3)-0-A-S-A-0-(S3)-(S2)-(S1)-H, H-(S2)-(S3)-(S1)-O-A-S-A-O-(S1)-(S3)-(S2)-H, H-(S3)-(S1)-(S2)-O-A-S-
A-O-(S2)-(S1)-(S3)-H, H-(S1)-(S2)-O-A-S-A-O-(S2)-(S1)-H, H-(S2)-(S3)-O-A-S-A-O-(S3)-(S2)-H, H-(S3)-(S1)-O-A-S-
A-O-(S1)-(S3)-H and H-(S1)-O-A-S-A-O-(S1)-H.
[0021] In above formula (I) or in any other formula of the description comprising a linker A represents any suitable
linker. Preferably A represents a linker containing up to 50 carbon atoms. This carbon atom based linker contains up to
60 carbon atoms and preferably up to 40 carbon atoms and more preferably between 1 and 26 carbon atoms and most
preferably between 2 and 20 carbon atoms. Such a linker may further contain between 1 to 30 oxygen atoms, 1 to 10
nitrogen atoms and 1 to 10 sulfur atoms. The function of the linker is to covalently connect the reducing-end of the
saccharides to an immunogenic carrier or to a solid support. Preferred are linkers A with are linear carbon chains
consisting of up to 50 carbon atoms. This carbon atom based linker contains up to 60 carbon atoms and preferably up
to 40 carbon atoms and more preferably between 1 and 26 carbon atoms and most preferably between 2 and 20 carbon
atoms. Also preferred are polyethylene glycol (PEG) linkers A comprising up to 60 carbon atoms and preferably up to
40 carbon atoms and more preferably between 4 and 26 carbon atoms and most preferably between 4 and 20 carbon
atoms. Also preferred are shorter linkers A selected from the following group: -CH2-O-CH2-, -CH2-CH2-O-CH2-, -CH2-O-
CH2-CH2-, -CH2-CH2-O-CH2-CH2-, -CH2-O-C2H4-O-CH2-, -CH2-CH2-O-C2H4-O-CH2-, -CH2-O-C2H4-O-CH2-CH2-,
-CH2-CH2-O-C2H4-O-CH2-CH2-. Especially preferred are linkers A of the following structure: -(CH2)w-, wherein w is an
integer 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 and wherein one, two, three or four hydrogen
atoms can be replaced independently of each other by one of the substituents mentioned in list disclosed four paragraphs
further down.
[0022] An interconnecting molecule according to the present invention refers to a bifunctional molecule containing
functional group X and functional group Y, wherein functional group X is capable of reacting with the terminal thiol group
on the linker A and the functional group Y is capable of binding to an immunogenic carrier or to a solid support.
[0023] The present invention refers to saccharides of the formula (I), wherein the linker per se or together with the
interconnecting molecule is capable of establishing, keeping and/or bridging a special distance between the reducing-
end monosaccharide and an immunogenic carrier or a solid support.
[0024] Thus, the term "linker" as used herein is a chain of at least one carbon atom and up to 50 carbon atoms, wherein
this chain of 1 to 50 carbon atoms may be linear or branched and may further contain 1 to 30 oxygen atoms and/or 1 to
10 nitrogen atoms and/or 1 to 10 sulfur atoms and/or 1 to 3 phenyl moieties and/or 1 to 3 saturated 3-, 4-, 5- or 6-
membered carbocyclic rings and/or 1 to 3 saturated 3-, 4-, 5-or 6-membered heterocyclic rings containing one or two
heteroatoms selected from O, N and S, wherein this chain, the phenyl moieties and/or the carbocyclic or heterocyclic
rings within said chain can be substituted with 1 to 10 substituents selected from the group consisting of:













=O (carbonyl group), -OH, -OCH3, -OC2H5, -OC3H73 -O-cyclo-C3H5, -OCH(CH3)2, -OC(CH3)3, -OC4H9, -OPh,
-OCH2-Ph, -OCPh3, -SCH3, -SC2H5, -SC3H7, -S-cyclo-C3H5, -SCH(CH3)2, -SC(CH3)3, -COCH3, -COC2H5,
-COC3H7, -CO-cyclo-C3H5, -COCH(CH3)2, -COC(CH3)3, -COOH, -COOCH3, -COOC2H5, -COOC3H7, -COO-cyclo-
C3H5, -COOCH(CH3)2, -COOC(CH3)3, -OOC-CH3, -OOC-C2H5, -OOC-C3H7, -OOC-cyclo-C3H5, -OOC-CH(CH3)2,
-OOC-C(CH3)3, -CONH2, -CONHCH3, -CONHC2H5, -CONHC3H7, -CONH-cyclo-C3H5, -CONH[CH(CH3)2],
-CONH[C(CH3)3],- CON(CH3)2, -CON(C2H5)2, -CON(C3H7)2, -CON(cyclo-C3H5)2, -CON[CH(CH3)2]2,
-CON[C(CH3)3]2, -NHCOCH3, -NHCOC2H5, -NHCOC3H7, -NHCO-cyclo-C3H5, -NHCO-CH(CH3)2, -NHCO-
C(CH3)3, -NHCO-OCH3, -NHCO-OC2H5, -NHCO-OC3H7, -NHCO-O-cyclo-C3H5, -NHCO-OCH(CH3)2, -NHCO-
OC(CH3)3, -NHCH3, -NHC2H5, -NHC3H7, -NH-cyclo-C3H5, -NHCH(CH3)2, -NHC(CH3)3, -N(CH3)2, -N(C2H5)2,
-N(C3H7)2, -N(cyclo-C3H5)2, -N[CH(CH3)2]2, -N[C(CH3)3]2, -NH-CO-NH2, -NH-CO-NHCH3, -NH-CO-NHC2H5, -NH-
CS-N(C3H7)2, -NH-CO-NHC3H7, -NH-CO-N(C3H7)2, -NH-CO-NH[CH(CH3)2], -NH-CO-NH[C(CH3)3], -NH-CO-
N(CH3)2, -NH-CO-N(C2H5)2, -NH-CO-NH-cyclo-C3H5, -NH-CO-N(cyclo-C3H5)2, -NH-CO-N[CH(CH3)2]2, -NH-CO-
N[C(CH3)3]2, cyclo-C3H5, cyclo-C4H7, cyclo-C5H9, cyclo-C6H11, cyclo-C7H13, cyclo-C8H15, -Ph, -CH2-Ph, -CPh3,
-CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, -C5H11, -CH(CH3)-C3H7,
-CH2-CH(CH3)-C2H5, -CH(CH3)-CH(CH3)2, -C(CH3)2-C2H5, -CH2-C(CH3)3, -CH(C2H5)2, -C2H4-CH(CH3)2, -C6H13,
-C7H15, -C8H17, -C3H6-CH(CH3)2, -C2H4-CH(CH3)-C2H5, -CH(CH3)-C4H9, -CH2-CH(CH3)-C3H7,
-CH(CH3)-CH2-CH(CH3)2, -CH(CH3)-CH(CH3)-C2H5, -CH2-CH(CH3)-CH(CH3)2, -CH2-C(CH3)2-C2H5,
-C(CH3)2-C3H7, -C(CH3)2-CH(CH3)2, -C2H4-C(CH3)3 and -CH(CH3)-C(CH3)3.
[0025] The terminal thiol group on the linker A is connected to one carbon atom of this chain, which is preferably a
terminal carbon atom thus having beside the sulfur atom of the terminal thiol group only one further carbon atom to
which this terminal carbon atom is connected. Also one carbon atom of this chain is connected to the oxygen atom of
the reducing-end monosaccharide of the saccharide of general formula (I).
[0026] Further, the present invention refers to synthetic saccharides of the formula (I), wherein the linker is a molecular
fragment capable of connecting the reducing-end monosaccharide of saccharides of general formula (I) via the thiol
group with an immunogenic carrier or a solid support, optionally by binding to at least one further interconnecting molecule.
[0027] More preferably A represents -A1-A2-A3-, -A1-A3-, -A1-, or -A1-A2- A4-A5-A3-, wherein
A1 and A4 represent independently of each other -(CH2)o-, -(CH2)m-, -(CH2)o-CHR1-(CH2)m-, -(CH2)o-CR1R2-(CH2)m-,
-(C2H4O)o-CH2-, -(C2H4O)o-C2H4-, -o-C6H4-, -m-C6H4-, -p-C6H4-,
A2 and A5 represent independently of each other -(CH2)o-, -(CH2)q-, -CHR3-, -CR3R4-, -O-, -S-, -S-S-, -CO-, -COO-, -O-
CO-, -NH-CO-, -CO-NH-, -NH-CO-NH-, -o-C6H4-, -m-C6H4-, -p-C6H4-, -NR7-, -CH=CH-,













A3 represents -(CH2)r-, -(CH2)r-CR5R6-(CH2)s-, -o-C6H4-, -m-C6H4-, -p-C6H4-,
R1 to R6 represent independently of each other -H, -NH2, -OH, -OCH3, -OC2H5, -OC3H7, cyclo-C3H5, cyclo-C4H7, cyclo-
C5H9, cyclo-C6H11, cyclo-C7H13, cyclo-C8H15, -Ph, -CH2-Ph, -CPh3, -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9,
-CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, -C5H11, -CH(CH3)-C3H7, -CH2-CH(CH3)-C2H5, -CH(CH3)-CH(CH3)2,
-C(CH3)2-C2H5, -CH2-C(CH3)3, -CH(C2H5)2, -C2H4-CH(CH3)2, -C6H13, -C3H6-CH(CH3)2, -C2H4-CH(CH3)-C2H5,
-CH(CH3)-C4H9, -CH2-CH(CH3)-C3H7, -CH(CH3)-CH2-CH(CH3)2,- CH(CH3)-CH(CH3)-C2H5, -CH2-CH(CH3)-CH(CH3)2,
-CH2-C(CH3)2-C2H5, -C(CH3)2-C3H7, -C(CH3)2-CH(CH3)2, -C2H4-C(CH3)3, -CH(CH3)-C(CH3)3, -CH=CH2,
-CH2-CH=CH2, -C(CH3)=CH2, -CH=CH-CH3, -C2H4-CH=CH2, -C7H15, -C8H17, -CH2-CH=CH-CH3, -CH=CH-C2H5,
-CH2-C(CH3)=CH2, -CH(CH3)-CH=CH, -CH=C(CH3)2, -C(CH3)=CH-CH3, -CH=CH-CH=CH2, -C3H6-CH=CH2,
-C2H4-CH=CH-CH3, -CH2-CH=CH-C2H5, -CH=CH-C3H7, -CH2-CH=CH-CH=CH2, -CH=CH-CH=CH-CH3, -CH2NH2,
-CH2OH, -CH2-CH2NH2, -C6H4-OCH3, -C6H4-OH3 -CH2-CH2-OCH3, -CH2-CH2OH, -CH2-OCH3, -CH2-C6H4-OCH3,
-CH2-C6H4-OH;
R7 and R8 represent independently of each other cyclo-C3H5, cyclo-C4H7, cyclo-C5H9, cyclo-C6H11, cyclo-C7H13, cyclo-
C8H15, -Ph, -CH2-Ph, -CPh3, -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9, -C≡CH, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3,
-C5H11, -CH(CH3)-C3H7, -CH2-CH(CH3)-C2H5, -CH(CH3)-CH(CH3)2, -C(CH3)2-C2H5, -CH2-C(CH3)3, -CH(C2H5)2,
-C2H4-CH(CH3)2, -C6H13, -C3H6-CH(CH3)2, -C2H4-CH(CH3)-C2H5, -CH(CH3)-C4H9, -CH2-C≡CH, -CH2-CH(CH3)-C3H7,
-CH(CH3)-CH2-CH(CH3)2, -CH(CH3)-CH(CH3)-C2H5, -CH2-CH(CH3)-CH(CH3)2, -CH2-C(CH3)2-C2H5, -C(CH3)2-C3H7,
-C(CH3)2-CH(CH3)2, -C2H4-C(CH3)3, -CH(CH3)-C(CH3)3, -CH=CH2, -CH2-CH=CH2, -C(CH3)=CH2, -CH=CH-CH3,
-C2H4-CH=CH2, -C7H15, -C8H17, -CH2-CH=CH-CH3, -CH=CH-C2H5, -CH2-C(CH3)=CH2, -CH(CH3)-CH=CH,
-CH=C(CH3)2, -C(CH3)=CH-CH3, -CH=CH-CH=CH2, -C3H6-CH=CH2, -C2H4-CH=CH-CH3, -CH2-CH=CH-C2H5, -C=C-
CH3, -CH=CH-C3H7, -CH2-CH=CH-CH=CH2, -CH=CH-CH=CH-CH3, -CH2NH2, -CH2OH, -CH2-CH2NH2, -C6H4-OCH3,
-C6H4-OH, -CH2-CH2-OCH3, -CH2-CH2OH, -CH2-OCH3, -CH2-C6H4-OCH3, -CH2-C6H4-OH;
o, m, r and s represent independently of each other an integer from 1 to 20;
p and q represent independently of each other an integer from 0 to 5.
[0028] Preferred are linkers wherein A represents A1 and A1 has the meanings as disclosed herein or preferably A1
represents -(CH2)m-, -(CH2)o-CHR1-(CH2)m-, -(CH2)o-CR1R2-(CH2)m- -(C2H4O)o-CH2- -(C2H4O)o-C2H4- -o-C6H4-,
-m-C6H4-, or -p-C6H4- and even more preferably -(CH2)m-, -(CH2)o-CHR1-(CH2)m-, -(CH2)o-CR1R2-(CH2)m-,
-(C2H4O)o-CH2-, -(C2H4O)o-C2H4-, wherein m, o, R1, and R2 have the meanings as disclosed herein and preferably -H,
-NH2, -OH, -OCH3, -OC2H5, -OC3H7, cyclo-C3H5, cyclo-C4H7, cyclo-C5H9, cyclo-C6H11, -Ph, -CH2-Ph, -CH3, -C2H5,
-C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -C5H11, -CH=CH2, -C≡CH, -CH2-CH=CH2, -CH=CH-CH3,- CH2NH2,
-CH2OH, -CH2-CH2NH2, -CH2-CH2-OCH3, -CH2-CH2OH, -CH2-OCH3, and more preferably -H, -NH2, -OH, -OCH3,
-OC2H5, -OC3H7, cyclo-C3H5, -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH=CH2, -CH2-CH=CH2, -CH2NH2, -CH2OH,
-CH2-CH2NH2, -CH2-CH2-OCH3, -CH2-CH2OH, -CH2-OCH3.
[0029] The compounds of the present invention bear basic and/or acidic substituents and they may form salts with
organic or inorganic acids or bases. Examples of suitable acids for such acid addition salt formation are hydrochloric
acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid,
p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid,













perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic
acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic
acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sul-
fanilic acid, camphorsulfonic acid, china acid, mandelic acid, o-methylmandelic acid, hydrogen-benzenesulfonic acid,
picric acid, adipic acid, d-o-tolyltartaric acid, tartronic acid, (o, m, p)-toluic acid, naphthylamine sulfonic acid, and other
mineral or carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base
form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
[0030] Examples for suitable inorganic or organic bases are, for example, NaOH, KOH, NH4OH, tetraalkylammonium
hydroxide, lysine or arginine and the like. Salts may be prepared in a conventional manner using methods well known
in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid,
selected out of the group mentioned above.
[0031] Further, it is also possible that the compounds of the present invention bear simultaneously basic and acid
groups. Further, it may also occur that these basic and acid groups appear to be in close vicinity to one another enabling
an intramolecular proton transfer from the acidic group the basic group. Therefore, in a preferred embodiment of the
present invention the compound of the formula (I) may be zwitterionic, bearing at least e.g. one -O- and one -NH3+ group.
[0032] Thus, the present invention relates to saccharides of general formula (I):
wherein A is a linker;
M, N and P represent independently of each other one of the following sugar fragments:
wherein the anomeric position of sugar fragment S1 can be linked only to -O-A-SH or to the sugar fragment S2, the
anomeric position of sugar fragment S2 can be linked only to -O-A-SH or to the sugar fragment S3 and the anomeric
position of sugar fragment S3 can be linked only to -O-A-SH or to the sugar fragment S1; n1, n2 and n3 are integers
selected from 0 and 1, wherein at least one of the integers n1, n2 and n3 is 1, and pharmaceutically acceptable salts of
these saccharides.
[0033] The inventive compounds of the present invention are saccharides of general formula (I):
wherein A is a linker;
[0034] M, N and P represent independently of each other one of the following sugar fragments:













wherein if the anomeric position of sugar fragment S1 is linked to another sugar fragment, then it is linked to sugar
fragment S2, and if the anomeric position of sugar fragment S2 is linked to another sugar fragment, then it is linked to
the sugar fragment S3, and if the anomeric position of sugar fragment S3 is linked to another sugar fragment, the it is
linked to the sugar fragment S1, and
n1, n2 and n3 are integers selected from 0 and 1, wherein at least one of the integers n1, n2 and n3 is 1,
and pharmaceutically acceptable salts of these saccharides.
[0035] Thus, included under the scope of the present invention are trissaccharides of general formula:
H-(S1)-(S2)-(S3)-O-A-SH, H-(S2)-(S3)-(S1)-O-A-SH, H-(S3)-(S1)-(S2)-O-A-SH; disaccharide of general formula:
H-(S1)-(S2)-O-A-SH, H-(S2)-(S3)-O-A-SH, H-(S3)-(S1)-O-A-SH, and monosaccharides of general formula: H-(S1)-O-
A-SH, H-(S3)-O-A-SH, wherein A is defined as a linker.
[0036] A preferred embodiment of the present application is directed to saccharides of general formula (I)




n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
and pharmaceutically acceptable salts of these saccharides.
[0037] More preferred are saccharides of general formula (I)
wherein A is a linker defined as above,
P represents S1,
N represents S2,
M represents S3 wherein n1 = n2 = n3 = 1 or wherein n1 = n2 = 1 and n3 = 0 or wherein n1 = 1 and n2 = n3 = 0 or
wherein n1 = 0 and n2 = n3 = 1 or wherein n1 = n2 = 0 and n3 = 1.
[0038] However, not part of the present invention is a disaccharide wherein the sugar fragment S3 is bound to the
linker and is bound to the sugar fragment S1. Consequently, also the corresponding disulfide intermediate is also not
part of the present invention. But, included in the scope of the present invention is a disaccharide wherein the sugar
fragment S1 is bound to the linker and is also bound to the sugar fragment S3.
[0039] In yet another preferred embodiment of the present invention, the compound according to the general formula
(I) is selected from the group comprising or consisting of:
α-2,4,6-trideoxy-4-amino-D-GalNAc-(1→4)-1-(2-thio)ethyl-α-D-GalAp














[0040] Another aspect of the present invention relates to the synthesis of saccharides of general formula (I):
wherein A is a linker defined as above,
M, N and P represent independently of each other one of the following sugar fragments:
wherein each moiety S1, S2, and S3 is not more than once present in the general formula (I), sugar fragment S1 cannot
be simultaneously bound to -O-A-SH and sugar fragment S2, sugar fragment S3 cannot be simultaneously bound to
-O-A-SH and sugar fragment S1 and sugar fragment S2 cannot be simultaneously bound to - O-A-SH and sugar fragment
S3, and n1, n2 and n3 are integers selected from 0 and 1, wherein at least one of the integers n1, n2 and n3 is 1 and
comprising the steps:
A1) Reacting the compound 2 of the formula:






















wherein P4 represents a protecting group, in order to obtain compound 4 of general formula:
wherein P1-P4 and A are defined as above;
and
performing removal of protecting groups P1-P4 on compound 4 to afford monosaccharide disulfide 5 of general
formula:
wherein A is defined as above, and wherein monosaccharide disulfide 5 is further treated with a reducing agent to
afford monosaccharide 6 of general formula:













wherein A is defined as above;
or
performing selective deprotection on compound 4 to afford compound 7 of general formula
wherein P5 is a protecting group and P1, P3, P4 and A are defined as above.
or
A2) Reacting compound 8 of general formula
wherein P6 and P7 represent protecting groups, with compound 3 to afford compound 9 of general formula
wherein P6, P7 and A are defined as above;














performing conversion of the azido group to acetamide and removal of the protecting groups P4, P6 and P7 on
compound 9 to afford monosaccharide disulfide 10 of general formula:
wherein A is defined as above and, wherein monosaccharide disulfide 10 is further treated with a reducing agent
to afford monosaccharide 11 of general formula:
wherein A is defined as above;
or
performing selective deprotection on compound 9 to afford compound 12 of general formula:
wherein P4, P7 and A are defined as above.
or













A3) Reacting compound 13 of general formula
wherein P8- P11 represent protecting groups, with compound 3 to afford compound 14 of general formula:
wherein P4, P8-P11 are defined as above
and
performing selective deprotection of compound 14 to afford compound 15 of general formula:
wherein P4, P8, P9, P11 and A are defined as above.
and
B1) Reacting compound 7 with compound 13 to afford compound 16 of general formula:













wherein P1, P3-P5, P8-P11 and A are defined as above;
and
performing removal of protecting groups P1, P3-P5, P8-P11 on compound 16 to afford disaccharide disulfide 17 of
general formula:
wherein A is defined as above and wherein disaccharide disulfide 17 is further treated with a reducing agent to
afford disaccharide 18 of general formula:













wherein A is defined as above;
or
performing selective removal of protecting group P10 on compound 16 to afford compound 19 of general formula:
wherein P1, P3-P5, P9, P9, P11 and A are defined as above.
or
B2) Reacting compound 15 with compound 8 to afford compound 20 of general formula:













wherein P4, P6-P9, P11 and A are defined as above;
and
performing conversion of the azido group to acetamide and removal of the protecting groups P4, P6-P9, P11 on
compound 20 to afford disaccharide disulfide 21 of general formula:
wherein A is defined as above and wherein disaccharide disulfide 21 is treated with a reducing agent to afford
disaccharide 22 of general formula:













wherein A is defined as above;
or
performing selective removal of protecting group P6 on compound 20 to afford compound 23 of general formula:
wherein P4, P7-P9, P11 and A are defined as above;
or
B3) Reacting compound 12 with compound 2 to afford compound 24 of general formula:













wherein P1-P4, P7 and A are defined as above;
and
performing conversion of the azido group to acetamide and removal of protecting groups P1-P4 and P7 on compound
24 to afford disaccharide disulfide 25 of general formula:
wherein A is defined as above, and wherein disaccharide disulfide 25 is further treated with a reducing agent to
afford disaccharide 26 of general formula:













wherein A is defined as above;
or
performing selective deprotection on compound 24 to afford compound 27 of general formula:
wherein P12 is a protecting group and P1, P3, P4, P7 and A are defined as above.
and
C1) Reacting compound 19 with compound 8 to afford compound 28 of general formula:













wherein P1, P3-P9, P11 and A are defined as above;
and
wherein protecting group P6 is replaced with protecting group P13 in order to obtain compound 29 of the following
chemical formula:













wherein P1, P3-P5, P7-P9, P11, P13 and A are defined as above;
and
conversion of compound 29 to trisaccharide disulfide 30 by conversion of the azide group in the acetamide group
and cleavage of the protecting group P1, P3-P5, P7-P9, P11, P13, wherein compound 30 is of general formula:
and wherein A is defined as above;
and
conversion of trisaccharide disulfide 30 to trisaccharide 31 by treatment with a reducing agent, wherein compound
31 is of general formula:
and wherein A is defined as above.














C2) Reacting compound 23 with compound 2 to afford compound 32 of general formula:
wherein P1 - P4, P7- P9, P11 and A are defined as above;
and
conversion of compound 32 to trisaccharide disulfide 33 by conversion of the azide group in the acetamide group
and cleavage of the protecting group P1 - P4, P7 - P9, P11, wherein compound 33 is of general formula:













wherein A is defined as above;
and
conversion of trisaccharide disulfide 33 to trisaccharide 34 by treatment with a reducing agent, wherein compound
34 is of general formula:
wherein A is defined as above;
or













C3) Reacting compound 27 with compound 13 to afford compound 34 of general formula:
wherein P1, P3, P4, P7-P11 and A are defined as above;
and
conversion of compound 35 to trisaccharide disulfide 36 by conversion of the azide group in the acetamide group
and cleavage of the protecting group P1, P3, P4, P7-P11, wherein compound 36 is of general formula:
wherein A is defined as above;
and
conversion of trisaccharide disulfide 36 to trisaccharide 37 by treatment with a reducing agent, wherein compound
37 is of general formula:













wherein A is defined as above.
[0041] The term "protecting group" as used herein refers to commonly used groups in organic synthesis, preferably
used for protection of amines, hydroxyl groups, thiols, imines, carbonyls, carboxyls or other common functional groups,
and particularly preferred for amines, hydroxyl groups, thiols and carboxyls.
[0042] More specifically, P1, P2, P5, P6, P8-P10, P12 and P13 preferably are suitable protecting groups for hydroxyl
groups, more preferably different suitable protecting groups for hydroxyl groups capable of being removed subsequently
one after another by a suitable sequence of deprotection reactions. Therefore protecting groups for hydroxyl groups,
namely P1, P2, P5, P6, P8-P10, P12 and P13 may be selected from the group consisting of or comprising: acetyl, benzyl,
isopropylidene, benzylidene, benzoyl, p-methoxybenzyl, p-methoxybenzylidene, p-methoxyphenyl, p-bromobenzyl, p-
bromobenzyledene, p-nitrophenyl, allyl, acetyl, isopropyl, p-bromobenzyl dimethoxytrityl, trityl, 2-naphthylmethyl, pyval-
oyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tert-butylmethoxphenylsilyl, triethylsilyl, trimethylsilyl,
2-trimethylsilylethoxymethyl, 9-fluorenylmethoxycarbonyl, benzyloxymethyl, methyloxymethyl, tert-butyloxymethyl,
methoxyethyloxymethyl.
[0043] More specifically, in a preferred embodiment of the present invention protecting groups P1, P5, P9, P9 and P12
may be benzyl, P2 may be benzylidene, P6 may be levulinyl, P10 may be 9-fluorenylmethoxycarbonyl and P13 may be
benzyloxymethyl.
[0044] Amines are generally protected as carbamates. Therefore, protecting group P7 may be selected from the group
consisting of or comprising tert-butyloxy carbonyl, 9-fluorenylmethoxy carbonyl, allyloxy carbonyl, 2,2,2-trichloroethyloxy
carbonyl, benzyloxy carbonyl; carbonyls such as trifluoro acetyl, trichloro acetyl, acetyl, benzoyl. More specifically, in a
preferred embodiment of the present invention P7 may be benzyloxy carbonyl.
[0045] Carboxylic acids are generally protected as esters. Therefore protecting groups P3 and P11 may be selected
from the group consisting of or comprising methyl, ethyl, allyl, isopropyl, tert-butyl, phenyl, benzyl, p-methoxybenzyl.
More specifically, in a preferred embodiment of the present invention protecting groups P3 and P11 may be methyl.
[0046] The protecting groups employed in the synthesis of saccharides of general formula (I) can be differentiated in
permanent protecting groups and temporary protecting groups. Permanent protecting groups are protecting groups that
are stable during the entire synthesis and that can be efficiently removed at the late stage of the synthesis. Such
permanent groups include, but they are not restricted to benzyl, benzylidene, benzoate, acetate, alkyl esters. The
temporary protecting groups are generally orthogonal protecting groups that can be selectively removed at different
levels of the synthesis to free hydroxyl groups for subsequent introduction of different substituents, including monosac-
charides or other protecting groups. The ingenious choice of protecting groups allows expedient access to a library of
saccharides of general formula (I) functionalized with a linker presenting a terminal thiol group for subsequent conjugation
to a carrier immunogen or a solid support.
[0047] A preferred embodiment of the present invention is directed to the synthesis of compounds of general formula (I)

















n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
comprising the steps:
A1) Reacting the compound 2 of the formula:
wherein P1-P3 represent protecting groups, with the compound 3 of the formula
wherein P4 represents a protecting group, in order to obtain compound 4 of general formula:
wherein P1-P4 and A are defined as above;
and
performing removal of protecting groups P1-P4 on compound 4 to afford monosaccharide disulfide 5 of general
formula:













wherein A is defined as above, and wherein monosaccharide disulfide 5 is further treated with a reducing agent to
afford monosaccharide 6 of general formula:
wherein A is defined as above;
or
performing selective deprotection on compound 4 to afford compound 7 of general formula
wherein P5 is a protecting group and P1, P3, P4 and A are defined as above.
or
A2) Reacting compound 8 of general formula













wherein P6 and P7 represent protecting groups, with compound 3 to afford compound 9 of general formula
wherein P6, P7 and A are defined as above;
and
performing conversion of the azido group to acetamide and removal of the protecting groups P4, P6 and P7 on
compound 9 to afford monosaccharide disulfide 10 of general formula:
wherein A is defined as above and, wherein monosaccharide disulfide 10 is further treated with a reducing agent
to afford monosaccharide 11 of general formula:













wherein A is defined as above.
or
A3) Reacting compound 13 of general formula
wherein P8-P11 represent protecting groups, with compound 3 to afford compound 14 of general formula:
wherein P4, P8-P11 are defined as above
and
performing selective deprotection of compound 14 to afford compound 15 of general formula:













wherein P4, P9, P9, P11 and A are defined as above.
and
B1) Reacting compound 7 with compound 13 to afford compound 16 of general formula:
wherein P1, P3-P5, P8-P11 and A are defined as above;
and
performing removal of protecting groups P1, P3-P5, P8-P11 on compound 16 to afford disaccharide disulfide 17 of
general formula:













wherein A is defined as above and wherein disaccharide disulfide 17 is further treated with a reducing agent to
afford disaccharide 18 of general formula:
wherein A is defined as above;
or
performing selective removal of protecting group P10 on compound 16 to afford compound 19 of general formula:













wherein P1, P3-P5, P9, P9, P11 and A are defined as above.
or
B2) Reacting compound 15 with compound 8 to afford compound 20 of general formula:
wherein P4, P6-P9, P11 and A are defined as above;
and
performing conversion of the azido group to acetamide and removal of the protecting groups P4, P6-P9, P11 on
compound 20 to afford disaccharide disulfide 21 of general formula:













wherein A is defined as above and wherein disaccharide disulfide 21 is treated with a reducing agent to afford
disaccharide 22 of general formula:
wherein A is defined as above.
and
C1) Reacting compound 19 with compound 8 to afford compound 28 of general formula:













wherein P1, P3-P9, P11 and A are defined as above;
and
wherein protecting group P6 is replaced with protecting group P13 in order to obtain compound 29 of the following
chemical formula:













wherein P1, P3-P5, P7-P9, P11, P13 and A are defined as above;
and
conversion of compound 29 to trisaccharide disulfide 30 by conversion of the azide group in the acetamide group
and cleavage of the protecting group P1, P3-P5, P7-P9, P11, P13, wherein compound 30 is of general formula:
and wherein A is defined as above;
and
conversion of trisaccharide disulfide 30 to trisaccharide 31 by treatment with a reducing agent, wherein compound
31 is of general formula:
and wherein A is defined as above.













[0048] The conversion of the saccharide disulfides 36, 33, 30, 25, 21, 17, 10 and 5 to the saccharides 37, 34, 31, 26,
22, 18, 11, and 6 respectively is performed in presence of a reducing agent. Known reducing agent for the person skilled
in the art include, but they are not restricted to: mercaptoethanol, ditriotheritol, tris(2-carboxyethyl)phosphine, magne-
sium/methanol, sodium/ammonia followed by ammonium chloride/chlorhydric acid. Preferably the conversion of the
saccharide disulfides to the corresponding saccharides is carried out with tris(2-carboxyethyl)phosphine.
[0049] It is preferred that the reaction between compounds 2 and 3, compounds 2 and 12, compounds 5* and 11*,
compounds 19* and 21*, compounds 2 and 23 is performed in an aprotic solvent in presence of (dimethylthio)methyl-
sulfonium trifluoromethanesulfonate (DMTST) and TTBPy. In addition activated molecular sieve (MS) such as 3A mo-
lecular sieve, 4A molecular sieves or 3A acid washed molecular sieves can be used. The reaction temperature is between
-20 °C and room temperature, preferably the temperature is between -10 °C and room temperature, more preferably
the temperature is between -5 °C and room temperature and most preferably the temperature is between 0 °C and room
temperature. The reaction is preferably carried out in an aprotic solvent such as acetonitrile, ether such as tetrahydro-
furane, diethylether or dioxane, halogenated solvents such as chloroform, methylene chloride and toluene.
[0050] It is also preferred that the reaction of compounds 13 and 7, compounds 8 and 3, compounds 12* and 9*,
compounds 13* and 2*, compounds 2* and 21*, compounds 2* and 11* , compounds 19 and 8, and compounds 8 and
15, is performed in an apolar aprotic solvent in presence of silyl triflate. Examples of silyl triflate include, but are not
restricted to trimethylsilyl trifluoromethanesulfonate, tert-butyl dimethyl trifluoromethanesulfonate, triiospropyl trifluorom-
tahnesulfonate. Suitable apolar aprotic solvents include diethylether, chloroform, methylene chloride and toluene. The
reaction temperature is between -20 °C and +20 °C, preferably the temperature is between -10 °C and +10 °C and more
preferably the temperature is between -5 °C and +5 °C and most preferably about 0 °C. Preferably, activated molecular
sieve (MS) such as 3A molecular sieve, 4A molecular sieves or 3A acid washed molecular sieves can be used.
[0051] Preferably the replacement of protecting group P6 on compound 28 with protecting group P13 to obtain compound
29 is performed in two steps, first involving first involving the reaction of compound 28 with hydrazine or a hydrazinium
salt in a mixture of polar and apolar solvents and second by treatment of the product obtained after the first step with
BnOCH2SCy, DMTST and TTBPy in an apolar solvent. For the first step, hydrazinium salts of weak acids are preferred
such as hydrazinium acetate or hydrazinium proprionate. The second step is preferably conducted in presence of
activated molecular sieves as the one mentioned above at a temperature preferably between -10 °C and 20 °C and
most preferably between 0 °C and 10 °C. Suitable apolar solvents are mentioned above. It was found that the replacement
of protecting group P6 with protecting group P13 is essential for avoiding side-reactions during the cleavage of the
permanent protecting group.
[0052] The conversion of compound 4 to 5, 16 to 17, 24 to 25, 13* to 27* and 20* to 22* requires cleavage of the
protecting group, and more specifically of the permanent protecting groups. The cleavage of said protecting groups
involves first cleavage of the base-labile protecting groups by treatment with a base in a mixture of polar aprotic solvent
and a polar protic solvent; and second cleavage of the protecting groups sensitive to hydrogenation by exposure to
sodium and ammonia in a mixture of polar protic solvents. For the first step suitable aprotic solvents include tetrahydro-
furan, ethyl acetate, acetone, N,N-dimethylformamide, acetonitrile and N,N-dimethylsulfoxide, which are mixed with a
suitable protic solvent such as water and alcohols including methanol, ethanol, propanol, isopropanol or tert-buthanol.
The basic cleavage of the protecting groups is preferably performed at room temperature comprised between 0 °C and
room temperature. Appropriate base for performing first step include lithium hydroxide, sodium hydroxide and potassium
hydroxide. The cleavage of the protecting groups sensitive to hydrogenation is conducted by exposure to sodium and
ammonia in a mixture of polar protic solvents such as alcohols at a temperature comprised between -78 °C and room
temperature. Optionally, lithium can be used as equivalent of sodium during the cleavage of the protecting groups
sensitive to hydrogenation.
[0053] Previous to the above mentioned cleavage of permanent protecting groups, the conversion of compounds 9
to 10, 20 to 21, 29 to 30, 32 to 33, 35 to 36, 25* to 26*, 23* to 24*, and 17* to 18* involves conversion of the azido group
in the acetamide group, which is preferably performed in presence of thioacetic acid and pyridine. An alternative method
is to conduct conversion of the azido group in the acetamide group in two steps: first chemoselective reduction of the
azido group, and then acetylation. The chemoselective reduction can be carried out using by hydrogenolysis on Pd/C
in presence of ammonia, ammonium acetate, triphenylphosphine or pyridine. The acetylation can be accomplished using
acetyl chloride or acetic anhydride in presence of a base.
[0054] The saccharides I, 5, 6, 10, 11, 17, 21, 25, 30, 33, 33, 36, 37, 27*, 26*, 25*, 24*, 22*, 20* and 18* bear basic
and/or acidic substituents and they may form salts with organic or inorganic acids or bases. Examples of suitable acids
for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid,
citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic
acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid,
lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-
hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesul-
fonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphorsulfonic acid, china acid, mandelic acid,













o-methylmandelic acid, hydrogen-benzenesulfonic acid, picric acid, adipic acid, d-o-tolyltartaric acid, tartronic acid, (o,
m, p)-toluic acid, naphthylamine sulfonic acid, and other mineral or carboxylic acids well known to those skilled in the
art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a
salt in the conventional manner.
[0055] The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such
as dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate. The free base forms
differ from their corresponding salt forms somewhat in certain physical properties, such as solubility in polar solvents,
but the salts are otherwise equivalent to their corresponding free base forms for purposes of this invention.
[0056] Examples for suitable inorganic or organic bases are, for example, NaOH, KOH, NH4OH, tetraalkylammonium
hydroxide, lysine or arginine and the like. Salts may be prepared in a conventional manner using methods well known
in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid,
selected out of the group mentioned above.
[0057] Further, it is also possible that the compounds of the present invention bear simultaneously basic and acid
groups. Further, it may also occur that these basic and acid groups appear to be in close vicinity to one another enabling
an intramolecular proton transfer from the acidic group the basic group. Therefore, in a preferred embodiment of the
present invention the compound of the formula (I) may be zwitterionic, bearing at least e.g. one -O- and one -NH3+ group.
[0058] This invention includes within its scope stoechiometric solvates including hydrates as well as compounds
containing variable amounts of water that may be produced by processes such as lyophilisation.
[0059] Thus, the synthesis of the saccharides of the general formula (I) may further comprise step D:
D) preparing a salt of the compound of general formula (I) or preparing a lyophilisate of the compound of general
formula (I) or of the salt of the compound of general formula (I).
[0060] In another preferred embodiment, the synthesis of intermediates of general formula (II) may further comprise
step D:
D) preparing a salt of the compound of general formula (II) or preparing a lyophilisate of the compound of general
formula (II) or of the salt of the compound of general formula (II).
[0061] In a preferred embodiment, the synthesis of saccharides of the general formula (I)




n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
may further comprise step D)
D) preparing a salt of the compound of general formula (I) or preparing a lyophilisate of the compound of general formula
(I) or of the salt of the compound of general formula (I).
Intermediates
[0062] Another aspect of the present invention is directed to intermediates of general formula (II):













wherein A is a linker;
M, N and P represent independently of each other one of the following fragments:
wherein each moiety S1, S2, and S3 is not more than once present in the general formula (II), sugar fragment S1 cannot
be simultaneously bound to -O-A-S- and sugar fragment S2, sugar fragment S3 cannot be simultaneously bound to -O-
A-Sand sugar fragment S1 and sugar fragment S2 cannot be simultaneously bound to -O-A-S- and sugar fragment S3, and
n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
and pharmaceutically acceptable salts of these saccharides.
[0063] Preferred are intermediates of general formula (II)




n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1
and pharmaceutically acceptable salts of these saccharides.
[0064] More preferred are intermediates of general formula (II)

















wherein n1 = n2 = n3 = 1 or wherein n1 = n2 = 1 and n3 = 0 or wherein n1 = 1 and n2 = n3 = 0 or wherein n1 = 0 and
n2 = n3 = 1 or wherein n1 = n2 = 0 and n3 = 1.
Glycoconjugates
[0065] Another aspect of the present invention refers to glycoconjugate obtained by reacting the saccharides of general
formula (I) with an immunogenic carrier. Said glycoconjugates proved to be efficient as a vaccine for immunization
against diseases associated with bacteria.
[0066] Saccharides are known by the person skilled in the art as generally TI-2 (T cell independent-2) antigens and
poor immunogens. TI-2 antigens are antigens, which are recognized only by mature B cells through the cross linking of
surface exposed immunoglobulin receptors. Without T cell help, no immunological memory is generated and neither
isotype switching from IgM to other IgG subclasses, nor B cells affinity maturation occurs. Moreover, saccharides are
known poor immunogens in humans due to the structural homology to human glycolipids and glycoproteins. Due to their
poor immunogenic properties, saccharides manifest poor ability to produce both antibody production by B cells, as well
as the formation of memory cells, features which are essential for the production of potent vaccines.
[0067] Therefore, to produce a potent saccharide-based vaccine, the saccharides of general formula (I) are conjugated
to an immunogenic carrier to provide glycoconjugates, which present increased immunogenicity in comparison with the
saccharide.
[0068] In this context the term "immunogenic carrier" is defined as a structure, which is conjugated to the saccharide
to form a glycoconjugate that presents an increased immunity in comparison with the saccharide per se. Thus, the
conjugation of the saccharides of general formula (I) to the immunogenic carrier has as effect the stimulation of the
immune response against the saccharide of general formula (I), without inducing an immune response against the said
immunogenic carrier.
[0069] Preferred immunogenic carriers are carrier proteins or glycosphingolipid with immunomodulatory properties.
For the person skilled in the art, a carrier protein is a protein selected from the group comprising or consisting of: a
diphtheria toxoid, a mutated diphtheria toxoid, a modified diphtheria toxoid, a mutated and modified diphtheria toxoid,
a tetanus toxoid, a modified tetanus toxoid, a mutated tetanus toxoid, outer membrane protein (OMP), bovine serum
albumin (BSA), keyhole limpet hemocyanine (KLH) or cholera toxoid (CT). The term "toxoid" as used herein refers to a
bacterial toxin (usually an exotoxin), whose toxicity has been inactivated or suppressed either by chemical (formalin) or
heat treatment, while other properties, typically immunogenicity, are maintained. A mutated toxoid as used herein is a
recombinant bacterial toxin, which has been amended to be less toxic or even non-toxic by amending the wild-type
amino acid sequence. Such a mutation could be a substitution of one or more amino acids. Such a mutated toxoid
presents on its surface a functionality that can react with the functional group Y of the interconnecting molecule to provide
a modified toxoid. Said functionality is known to the person skilled in the art and includes, but is not restricted to the
primary amino functionality of a lysine residue that can react with activated esters, an isocyanate group or an aldehyde
in presence of a reducing agent, to the carboxylate functionality of a glutamate or aspartate residue that can be activated
by carbodiimides or to the thiol functionality of a cysteine residue. Activated esters include N-(γ-maleimidobutyryloxy)
sulfosuccinimide ester (sulfo-GMBS), succinimidyl (4-iodoacetyl) aminobenzoate (sulfo-SIAB), succinimidyl-3-(bromoa-
cetamido)propionate (SBAP), disuccinimidyl glutarat (DSG), 2-pyridyldithiol-tetraoxatetradecane-N-hydroxysuccinimide
(PEG-4-SPDP). The cysteine residue on the carrier protein can be converted to the corresponding dehydroalanine that
can be further reacted with a suitable interconnecting molecule to provide modified carrier protein having on their surface
the functional group X of the interconnecting molecule. In this case the functional group Y on the interconnecting molecule
might be a thiol group and the group X might be an alkene. Such interconnecting molecules include allylmercaptan.
After reaction with such interconnecting molecule, the carrier protein is converted to a modified carrier protein presenting
the vinyl group X of the interconnecting molecule, which is suitable to react with the saccharides of general formula (I).
[0070] It is especially preferred that the saccharide of general formula (I), and preferably saccharide 37, 34, 31, 26,
22, 18, 11 and 6 is conjugated to the non-toxic mutated diphtheria toxin CRM197 presenting as a functionality a primary
amine functionality of a lysine residue..
[0071] CRM197 like wild-type diphtheria toxin is a single polypeptide chain of 535 amino acids (58 kD) consisting of
two subunits linked by disulfide bridges having a single amino acid substitution of glutamic acid for glycine. It is utilized
as a carrier protein in a number of approved conjugate vaccines for diseases such as Prevnar.
[0072] Thus, in a preferred embodiment of the present invention the carrier protein presents on its surface primary
amino functionalities of lysine residues that are able to react with the functional group Y of the interconnecting molecule
to provide modified carrier protein having on their surface said functional group X of the interconnecting molecule, which













is able to react with the terminal thiol group of the linker of the compounds of general formula (I). Said functional group
X of the interconnecting molecules is selected of the group comprising or consisting of maleimide; α-iodoacetyl; α-
bromoacetyl; N-hydroxysuccinimide ester (NHS), 2-pyridyldithiols, thiol and vinyl (see Figure 3).
[0073] Preferably, the saccharide of general formula (I) is conjugated to the non-toxic mutated diphtheria toxin CRM197,
which is modified by maleimide. In yet another preferred embodiment, the saccharide of general formula (I) is conjugated
to the non-toxic mutated diphtheria toxin CRM197, which is modified by vinyl. In the most preferred embodiment, the
compound of general formula (I) is conjugated to the non-toxic mutated diphtheria toxin CRM197, which is modified by
α-bromoacetamide.
[0074] In another embodiment, said immunogenic carrier is preferably a glycosphingolipid with immunomodulatory
properties, and more preferably (2S,3S,4R)-1-(α-D-galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol. The
term glycosphingolipid with immunomodulatory properties, as used herein, refers to a suitable glycosphingolipid capable
of stimulating the immune system’s response to a target antigen, but which does not in itself confer immunity as defined
above.
[0075] Glycoshingolipids as used herein are compounds containing a carbohydrate moiety α-linked to a sphingolipid.
Preferably, the carbohydrate moiety is a hexopyranose and most preferably is α-D-galactopyranose. For the person
skilled in the art, sphingolipids are a class of lipids containing a C18 amino alcohol connected via an amide bond to a
fatty acid. The C18 amino alcohol is preferably mono-, di- or polysubstituted with hydroxyl groups. Especially preferred,
the C18 amino alcohol is phytosphingosine. The fatty acid is preferably a monocarboxylic acid having a saturated alkyl
chain of a number of carbons ranging from 16 to 28 and more preferably from 18 to 26. Glycosphingolipids with immu-
nomodulatory properties include, but they are not restricted to (2S,3S,4R)-1-(α-D-galactopyranosyl)-2-hexacosanoylami-
nooctadecane-3,4-diol, which can stimulate natural killer (NK) activity and cytokine production by natural killer T (NKT)
cells and exhibits potent antitumor activity in vivo (Proc. Natl Acad. Sci. USA, 1998, 95, 5690).
[0076] The conjugates of the compounds of general formula (I) to the glycosphingolipid with immunomodulatory prop-
erties have the advantage of being heat stable. To be suitable for conjugation, on the glycosphingolipid with immu-
nomodulatory properties a functionality is introduced. Said functionality is prone to react directly with the terminal thiol
group of the linker of the saccharides of general formula (I) to provide glycoconjugates of the saccharides of general
formula (I) or with the functional group Y of the interconnecting molecule to provide the modified glycosphingolipid with
immunomodulatory properties.
[0077] Preferably, said functionality is introduced at the C6 of the carbohydrate moiety of the glycosphingolipid with
immunomodulatory properties. Thus, the glycosphingolipid with immunomodulatory properties is functionalized with a
functionality, which is prone of reacting with thiol group, activated ester, isocyanate group, aldehyde, vinyl, amino group
and azido group to provide directly the glycoconjugate of the saccharides of general formula (I) or the modified gly-
cosphingolipid with immunomodulatory properties presenting the functional group X of the interconnecting molecule.
[0078] Preferably, the functionality introduced at the C6 of the carbohydrate moiety of the glycosphingolipid with
immunomodulatory properties is selected from the group comprising or containing an amine, a thiol, an alcohol, a
carboxylic acid, a vinyl, maleimide; α-iodoacetyl; α-bromoacetyl; N-hydroxysuccinimide ester (NHS), 2-pyridyldithiols.
[0079] Said functional group X of the interconnecting molecules is selected of the group comprising or consisting of
maleimide; α-iodoacetyl; α-bromoacetyl; N-hydroxysuccinimide ester (NHS), 2-pyridyldithiols, thiol and vinyl.
[0080] It was found that the glycoconjugates obtained by reacting the saccharides of general formula (I) with an
immunogenic carrier are suitable to elicit an immune response in an animal, and therefore are useful as a vaccine for
immunization against diseases associated with bacteria containing in their capsular polysaccharide a saccharide structure
selected from:
[0081] Preferably, the bacteria containing in the capsular polysaccharide a one of the above mentioned saccharide






















[0082] In a preferred embodiment the glycoconjugates obtained by reacting the saccharides of general formula (I)
with an immunogenic carrier are useful as a vaccine for immunization against diseases associated with bacteria, wherein
said diseases include pneumonia, meningitis, otitis media, bacteremia and acute exacerbation of chronic bronchitis,
sinusitis, arthritis and conjunctivitis
[0083] One aspect of the present invention relates to pharmaceutical compositions, especially vaccines comprising
at least one glycoconjugate obtained by reacting any saccharide of general formula (I) with an immunogenic carrier,
and/or one saccharide of general formula (I) and/or a intermediate of general formula (II), together with at least one
pharmaceutically acceptable cryoprotectant, lyoprotectant, excipient and/or diluent.
[0084] Said vaccine may be prepared in the form of a suspension or may be lyophilized. The suspension form may
be stored frozen. In the lyophilized form, it is preferable to add one or more stabilizers. Optionally, one or more adjuvants
may be added as well. Any conventional stabilizers and adjuvants may be included in a vaccine according to this invention.
[0085] The term "adjuvant" as used herein refers to an immunological adjuvant i.e. a material used in a vaccine
composition that modifies or augments the effects of said vaccine by enhancing the immune response to a given antigen
contained in the vaccine without being antigenically related to it. For the persons skilled in the art, classically recognized
examples immunological adjuvants include but are not restricted to oil emulsions (e.g., Freund’s adjuvant), saponins,
aluminium or calcium salts (e.g., alum), non-ionic block polymer surfactants, and many others.
[0086] Vaccination can be performed at any age. The vaccine many be administered subcutaneously, by spray, by
injection, orally, intraocularly, intratracheally or nasally.
[0087] Another aspect of the present invention relates to pharmaceutical formulations and pharmaceutical compositions
containing the vaccine as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient,
solvent and/or diluents.
[0088] Further preferred, the pharmaceutical composition is formulated in the form of a lyophilisate or liquid buffer
solution.
[0089] The vaccine can also be administered in form of its pharmaceutically active salt optionally using substantially
nontoxic pharmaceutically acceptable carrier, excipients, adjuvants or diluents. The vaccine of the present invention is
prepared in a conventional solid or liquid carrier or diluents and a conventional pharmaceutically-made adjuvant at
suitable dosage level in a known way. The preferred preparations and formulations are in administrable form which is
suitable for oral application. These administrable forms, for example, include pills, tablets, film tablets, coated tablets,
capsules, powders and deposits. Other than oral administratable forms are also possible. The inventive vaccine may
be administered by any appropriate means, including but not limited to inhalation, injection (intravenous, intraperitoneal,
intramuscular, subcutaneous) by absorption through epithelial or mucocutaneous linings (oral mucosa, rectal and vaginal
epithelial linings, nasopharyngial mucosa, intestinal mucosa); orally, rectally, transdermally, topically, intradermally,
intragastrically, intracutaneously, intravaginally, intravasally, intranasally, intrabuccally, percutaneously, sublingually, or
any other means available within the pharmaceutical arts.
[0090] The vaccine of the present invention, containing the glycoconjugate obtained by reacting the saccharide of
general formula (I) with an immunogenic carrier or pharmaceutically acceptable salts thereof as an active ingredient will
typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form
of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution,
oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical
practices. For example, for oral administration in the form of tablets or capsules, the active ingredient may be combined
with any oral nontoxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium
stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when
desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in
the mixture.
[0091] Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as
acacia, sodium alginate, carboxymethyl-cellulose, polyethylene glycol and waxes. Among the lubricants that may be
mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like.
Disintegrants include starch, methylcellulose, guar gum and the like. Sweetening and flavoring agents and preservatives
may also be included where appropriate. Some of the terms noted above, namely disintegrants, diluents, lubricants,
binders and the like, are discussed in more detail below.
[0092] Additionally, the vaccine of the present invention may be formulated in sustained release form to provide the
rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects.
Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or
controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules
containing such impregnated or encapsulated porous polymeric matrices.
[0093] Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned
water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral
solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.













[0094] Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in
combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
[0095] For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter
is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten
homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidifies.
[0096] Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form
preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
[0097] The vaccine of the present invention may also be deliverable transdermally. The transdermal compositions
may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix
or reservoir type as are conventional in the art for this purpose.
[0098] The term capsule refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or
denatured gelatins or starch for holding or containing compositions comprising the active ingredients. Hard shell capsules
are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain
small amounts of dyes, opaquing agents, plasticizers and preservatives.
[0099] Tablet means compressed or molded solid dosage form containing the active ingredients with suitable diluents.
The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or
by compaction well known to a person skilled in the art.
[0100] Oral gels refer to the active ingredients dispersed or solubilized in a hydrophilic semi-solid matrix.
[0101] Powders for constitution refer to powder blends containing the active ingredients and suitable diluents which
can be suspended in water or juices.
[0102] Suitable diluents are substances that usually make up the major portion of the composition or dosage form.
Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol, starches derived from wheat, corn rice
and potato, and celluloses such as microcrystalline cellulose. The amount of diluents in the composition can range from
about 5 to about 95% by weight of the total composition, preferably from about 25 to about 75%, more preferably from
about 30 to about 60% by weight, and most preferably from about 40 to 50% by weight.
[0103] The term disintegrants refers to materials added to the composition to help it break apart (disintegrate) and
release the medicaments. Suitable disintegrants include starches, "cold water soluble" modified starches such as sodium
carboxymethyl starch, natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar, cellulose
derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses and cross-linked
microcrystalline celluloses such as sodium croscarmellose, alginates such as alginic acid and sodium alginate, clays
such as bentonites, and effervescent mixtures. The amount of disintegrant in the composition can range from about 1
to about 40% by weight of the composition, preferably 2 to about 30% by weight of the composition, more preferably
from about 3 to 20% by weight of the composition, and most preferably from about 5 to about 10% by weight.
[0104] Binders characterize substances that bind or "glue" powders together and make them cohesive by forming
granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the
diluents or bulking agent. Suitable binders include sugars such as sucrose, starches derived from wheat, corn rice and
potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate
and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and
hydroxypropyl-methylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate. The amount
of binder in the composition can range from about 1 to 30% by weight of the composition, preferably from about 2 to
about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably
from about 3 to about 6% by weight.
[0105] Lubricant refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been
compressed, to release from the mold or die by reducing friction or wear. Suitable lubricants include metallic stearates
such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water
soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and
D, L-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the
surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition
can range from about 0.05 to about 15% by weight of the composition, preferably 0.2 to about 5% by weight of the
composition, more preferably from about 0.3 to about 3%, and most preferably from about 0.3 to about 1.5% by weight
of the composition.
[0106] Glidents are materials that prevent caking and improve the flow characteristics of granulations, so that flow is
smooth and uniform. Suitable glidents include silicon dioxide and talc. The amount of glident in the composition can
range from about 0.01 to 10% by weight of the composition, preferably 0.1 % to about 7% by weight of the total composition,
more preferably from about 0.2 to 5% by weight, and most preferably from about 0.5 to about 2% by weight.
[0107] Coloring agents are excipients that provide coloration to the composition or the dosage form. Such excipients
can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide.
The amount of the coloring agent can vary from about 0.01 to 10% by weight of the composition, preferably from about













0.05 to 6% by weight, more preferably from about 0.1 to about 4% by weight of the composition, and most preferably
from about 0.1 to about 1 %.
[0108] Techniques for the formulation and administration of the vaccine of the present invention may be found in
"Remington’s Pharmaceutical Sciences" Mack Publishing Co., Easton PA. A suitable vaccine composition comprising
at least one glycoconjugate of the present invention and/or pharmaceutically acceptable salts thereof may be a solution
of one glycoconjugate obtained by reacting any saccharide of general formula (I) with an immunogenic carrier in a
suitable liquid pharmaceutical carrier or any other formulation such as tablets, pills, film tablets, coated tablets, dragees,
capsules, powders and deposits, gels, syrups, slurries, suspensions, emulsions, and the like.
[0109] A therapeutically effective dosage of one glycoconjugate obtained by reacting any saccharide of general formula
(I) with an immunogenic carrier refers to that amount of the compound that results in an at least a partial immunization
against a disease. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical,
pharmacological, and toxicological procedures in cell cultures or experimental animals. The dose ratio between toxic
and therapeutic effect is the therapeutic index. The actual amount of the composition administered will be dependent
on the subject being treated, on the subject’s weight, the severity of the affliction, the manner of administration and the
judgement of the prescribing physician.
[0110] Another preferred embodiment of the present invention is directed to pharmaceutical composition comprising
the glycoconjugate obtained by reacting any saccharide of general formula (I) with an immunogenic carrier, and/or the
saccharide of general formula (I), and/or the intermediate of general formula (II) together with at least one one pharma-
ceutically acceptable cryoprotectant, lyoprotectant, excipient and/or for immunization against diseases associated with
Streptococcus pneumoniae bacteria.
[0111] Streptococcus pneumoniae bacteria referred herein include the following serotypes Streptococcus pneumoniae
type 4, Streptococcus pneumoniae type 9V, Streptococcus pneumoniae type 2, Streptococcus pneumoniae type 19F,
Streptococcus pneumoniae type 3, Streptococcus pneumoniae type 19A, Streptococcus pneumoniae type 12F, Strep-
tococcus pneumoniae type 31, Streptococcus pneumoniae type 7F, Streptococcus pneumoniae type 5, Streptococcus
pneumoniae type 14, Streptococcus pneumoniae type 6A, Streptococcus pneumoniae type 6B, Streptococcus pneu-
moniae type 18C and Streptococcus pneumoniae type 23F.
[0112] A preferred embodiment of the present invention is directed to a pharmaceutical composition, especially a
vaccine comprising the glycoconjugate obtained by reacting any saccharide of general formula (I) with an immunogenic
carrier for immunization against diseases associated with Streptococcus pneumoniae type 1 and type 3.
[0113] The saccharides derived from [→3)-β-D-GlcAp-(1→4)-β-D-Glc(1→] are functionalized with suitable linker, which
allows their conjugation to an immunogenic carrier, as defined herein to provide glycoconjugates. Said glycoconjugates
proved to be efficient as a vaccine for immunization against diseases associated with bacteria, and in particularly against
diseases associated with Streptococcus pneumoniae, and particularly against Streptococcus pneumoniae type 3. In
particular, the glycoconjugates obtained by reacting saccharide of general formula (I) with glycosphingolipids with im-
munomodulatory properties according to the present invention, were able to elicit in mice immunized with said glyco-
conjugates, high titer of antibodies specific to the saccharides of general formula (I). Said diseases include pneumonia,
meningitis, otitis media, bacteremia and acute exacerbation of chronic bronchitis, sinusitis, arthritis and conjunctivitis.
[0114] Yet another aspect of the present invention refers to saccharide of general formula (I) useful as a marker in
immunological assays for diagnostics of diseases caused by bacteria containing in the capsular polysaccharide a sac-
charide structure selected from:
[0115] Such assays comprise, for instance, microarray and ELISA useful for diagnosis of diseases caused by bacteria
containing or comprising the saccharides of the present invention, said diseases including pneumonia, meningitis, otitis
media, bacteremia and acute exacerbation of chronic bronchitis, sinusitis, arthritis and conjunctivitis.






















for diagnosis of diseases caused by bacteria containing or comprising the saccharides of the present invention. Said
solid supports present on their surface a functionality that is prone to react with the functional group Y of the interconnecting
molecule to provide modified solid supports, presenting on their surface the functional group X of the interconnecting
molecule, which are able to react with the thiol group of saccharides of general formula (I). Said solid supports include,
but are not restricted to microarray slides, which present on their surface a functionality that is prone to react with the
functional group Y of the interconnecting molecule to provide modified microarray slides, presenting of their surface the
functional group X of the interconnecting molecule. Preferably, the microarray slides present on their surface an amino
group. Microarray slides presenting on their surface an amino group include, but are not restricted to amine-coated
GAPS II slides (Corning) or CodeLink NHS slides on which the amino functionality was introduced by incubation with
Bovin Serum Albumin (BSA).
[0117] Microarray slides coated with the saccharides of general formula (I) were synthesized by conjugating the
sacharides of general formula (I) to said modified microarray slides, and incubated with rabbit anti-SP1 typing serum or
human pneumococcal serum 007sp in the presence or absence of native SP1 polysaccharide. The binding experiments
show that both rabbit anti-SP1 typing serum and human pneumococcal serum 007sp bound to α-2,4,6-trideoxy-4-amino-
D-GalNAc-(1→4)-α-D-GalAp-(1→3)-α-D-GalAp and α-D-GalAp-(1→3)-α-D-GalAp saccharide structures (see Figures
4-8). Moreover, the binding could be inhibited with the native SP1 polysaccharide, suggesting that the saccharides
according top the present invention share epitopes that are recognized by the immune system (see Figure 4 and Figure 5).
Description of the figures
[0118]
Figure 1 shows the global distribution of Streptococcus pneumoniae serotypes
Figure 2 provides examples of interconnecting molecules according to the present invention.
Figure 3 provides examples of functional group X of the interconnecting molecule according to the present invention.
Figure 4 shows the printing pattern of the saccharides of general formula (I) on microarray slides
Figure 5 shows the binding of human pneumococcal serum 007sp (pooled sera of 287 humans immunized with
Pneumovax vaccine) to saccharides of general formula (I), which are coated on modified CodeLink NHS slides in
presence and in absence of native SP1 polysaccharide.
Figure 6 shows the binding of the rabbit anti-SP1 typing serum to saccharides of general formula (I), which are
coated on modified amine-coated GAPS II slides (Corning) in presence and in absence of native SP1 polysaccharide.
Figure 7 shows the binding of the rabbit anti-SP1 typing serum to saccharides of general formula (I), which are
coated on modified amine-coated GAPS II slides (Corning).
Figure 8 shows the binding of the rabbit anti-SP1 typing serum to saccharides of general formula (I), which are
coated on modified CodeLink NHS slides.
[0119] The following examples are included to demonstrate preferred embodiments of the invention. It should be
appreciated by those of skill in the art that the techniques disclosed in the examples, which follow represent techniques
discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute
preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate
that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result
without departing from the spirit and scope of the invention.
[0120] Further modifications and alternative embodiments of various aspects of the invention will be apparent to those
skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for
the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood
that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and
materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and
certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after
having the benefit of this description of the invention. Changes may be made in the elements described herein without
departing from the spirit and scope of the invention as described in the following claims.















[0121] General information for chemical synthesis. Commercial reagents were used without further purification except
where noted. Solvents were dried and redistilled prior to use in the usual way. All reactions were performed in oven-
dried glassware under an inert atmosphere unless noted otherwise. Analytical thin layer chromatography (TLC) was
performed on Kieselgel 60 F254 glass plates precoated with a 0.25 mm thickness of silica gel. The TLC plates were
visualized with UV light and by staining with Hanessian solution (ceric sulfate and ammonium molybdate in aqueous
sulfuric acid) or sulfuric acid-ethanol solution. Column chromatography was performed on Fluka Kieselgel 60 (230-400
mesh). Optical rotations (OR) were measured with a Schmidt & Haensch UniPol L1000 polarimeter at a concentration
(c) expressed in g/100 mL. 1H and 13C NMR spectra were measured with a Varian 400-MR or Varian 600 spectrometer
with Me4Si as the internal standard. NMR chemical shifts (δ) were recorded in ppm and coupling constants (J) were
reported in Hz. High-resolution mass spectra (HRMS) were recorded with an Agilent 6210 ESI-TOF mass spectrometer
at the Freie Universität Berlin, Mass Spectrometry Core Facility.
[0122] Example 1: 4-(Benzyloxycarbonyl)amino-3-O-levulinoyl-4,6-dideoxy-D-galactal (1*): To a stirred solution
of 4-O-(benzyloxycarbonyl)amino-3-hydroxy-4,6-dideoxy-D-galactal (Org. Lett. 2010, 12, 1624) (1.64 g, 6.21 mmol)
(1.64 g, 6.21 mmol) in CH2Cl2 (40 ml) were added at 0 °C pyridine (0.501 ml, 6.21 mmol), levulinic acid (0.96 ml, 9.31
mmol), DMAP (0.152 g, 1.242 mmol) and EDC (1.205 ml, 6.83 mmol). The mixture was warmed to room temperature
and stirred at that temperature. After 3 h, 0.5 eq. levulinic acid and 0.5 eq. EDC were added to drive the reaction to
completion. After 5 h, the mixture was diluted with 100 ml DCM and washed with water (50 ml), sat. aq. NH4Cl (50 ml),
sat. aq. NaHCO3 (50 ml) and brine (50 ml). The organic fraction was dried over Na2SO4 and concentrated. The residue
was purified by flash chromatography (EtOAc/hexanes 1:1) to give ester 1* (2.07 g, 5.73 mmol, 92%) as a clear oil.
HRMS (ESI) calcd for C19H23NO6 (M+Na+) 384.1423 found 384.1415 m/z.
[0123] Example 2: Dibutyl [2-azido-4-(benzyloxycarbonyl)amino-3-O-levulinoyl-2,4,6-trideoxy-D-galacto-
pyranosyl] phosphate (2*): To a stirred solution of galactal 1* (3.17 g, 8.77 mmol) in dry MeCN (44 ml) were added at
-25°C ceric ammonium nitrate (14.42 g, 26.3 mmol) and sodium azide (0.86 g, 13.15 mmol). The reaction was stirred
vigorously between -25 °C and -20 °C for 6 h. The mixture was diluted with cold Et2O (50 ml). The organic layer was
washed with cold water (3x30 ml), dried over Na2SO4 and concentrated. The residue was filtered through a plug of silica
gel (EtOAc/hexanes/Et3N 1:1:0.01) to give the crude glycosyl nitrate as 4:1 galacto/talo mixture (2.01 g) as a slightly
yellow oil.
[0124] To the crude glycosyl nitrate (2.01 g) was added at room temperature a solution of cesium dibutyl phosphate
(2.21 g, 6.45 mmol) in dry DMF (28 ml). The mixture was stirred at that temperature for 4.5 h, diluted with EtOAc (100
ml) and poured into water (100 ml). The organic phase was washed with water (5x50 ml) and the combined aqueous
fractions were extracted with EtOAc (50 ml). The organic phase was dried over Na2SO4 and concentrated. The residue
was purified by flash chromatography (EtOAc/hexanes 45:55 to 50:50) to give glycosyl phosphate 2* (1.84 g, 3.00 mmol,
37%, 1:10 α/β) as a clear oil. HRMS (ESI) calcd for C27H41N4O10P (M+Na+) 635.2458 found 635.2422 m/z.
[0125] Example 3: Ethyl 2-O-benzyl-3,4-isopropylidene-1-thio-β-D-galactopyranoside (3*): To a stirred solution
of ethyl 6-O-tert-butyldimethylsilyl-3,4-isopropylidene-1-thio-β-D-galactopyranoside (Bioorg. Med. Chem. 2001, 9, 1395)
(45.7 g, 121 mmol) in DMF (150 ml) and THF (75 ml) were added at 0 °C portionwise sodium hydride (60%, 7.24 g, 181
mmol) and then benzyl bromide (17.2 ml, 145 mmol). The mixture was stirred for 1 h at 0 °C, slowly warmed to room
temperature and stirred for 16 h at that temperature. The reaction was quenched at 0 °C with sat. aq. NH4Cl (20 ml),
diluted with water (200 ml) and EtOAc (150 ml) and stirred for 15 min at 0°C. After separation, the organic phase was
washed with water (5x100 ml) and the combined aqueous fractions were re-extracted with EtOAc (2x100 ml). The
combined organic extracts were dried over Na2SO4 and concentrated to give the crude benzyl ether (61 g) as a yellow oil.
To a stirred solution of the crude benzyl ether (61 g) in THF (370 ml) was added at 0 °C tetrabutylammonium fluoride
(1 M in THF, 166 ml, 166 mmol). The mixture was warmed to room temperature and stirred for 1 h. The reaction was
diluted with sat. aq. NaHCO3 (200 ml) and EtOAc (100 ml). After separation, the aqueous phase was extracted with
EtOAc (3x100 ml), the combined organic fractions were dried over MgSO4 and concentrated. The residue was purified
by flash chromatography (EtOAc/hexanes 0:1 to 1:3 to 1:1) to give alcohol 3* as a white solid. HRMS (ESI) calcd for
C18H26O5S (M+Na+) 377.1398 found 377.1416 m/z.
[0126] Example 4: Methyl (ethyl 2-O-benzyl-1-thio-β-D-galactopyranosid)uronate (4*): To a vigorously stirred
solution of alcohol 4* (6.0 g, 16.93 mmol) in CH2Cl2 (50 ml) and H2O (25 ml) were added at 0 °C TEMPO (0.53 g, 3.39
mmol) and BAIB (10.9 g, 33.9 mmol). The mixture was warmed to room temperature and stirred for 1 h at that temperature.
The reaction was quenched with 10% aq. Na2S2O3 (10 ml) and diluted with EtOAc (30 ml). After separation, the organic
phase was washed with 10% Na2S2O3 (4x20 ml). The aqueous phase was extracted with EtOAc (2x20 ml) and the
combined organic fractions were dried over Na2SO4 and concentrated to give the crude acid (7.92 g) as yellow oil.
To a stirred solution of acetyl chloride (6.04 ml, 85 mmol) in MeOH (300 ml) was added dropwise at 0 °C a solution of













the crude acid (7.92 g) in MeOH (40 ml). The mixture was warmed to room temperature, stirred for 2 h at that temperature
and cooled to 0 °C. The reaction was quenched with sat. aq. NaHC03 (30 ml) and neutralized to pH 7 with solid NaHCO3.
The volatiles were evaporated and the mixture was diluted with EtOAc (70 ml). After separation, the aqueous phase
was extracted with EtOAc (5x50 ml). The combined organic fractions were dried over Na2SO4 and concentrated. Flash
chromatography was performed (EtOAc/hexanes 2:3 to 1:1, then 1:0) to give the crude product, which was crystallized
in methanol at - 20 °C (5 ml/g crude product) to give diol 4* (3.47 g, 10.13 mmol, 60%) as a white solid. HRMS (ESI)
calcd for C16H22O6S (M+Na)+ 365.1034 found 365.1058 m/z.
[0127] Example 5: Methyl (ethyl 2-O-benzyl-3,4-O-endo-benzylidene-1-thio-β-D-galactopyranosid)uronate (5*)
and Methyl (ethyl 2-O-benzyl-3,4-O-exo-benzylidene-1-thio-β-D-galactopyranosid)uronate (6*): To a stirred solu-
tion of diol 4* (2.99 g, 8.73 mmol) in dry acetonitrile (29 ml) were added at room temperature benzaldehyde dimethyl
acetal (6.57 ml, 43.6 mmol) and DL-camphorsulfonic acid (0.51 g, 2.18 mmol). The mixture was stirred at room temper-
ature for 5 h and the reaction was quenched by addition of triethylamine (0.35 ml). The mixture was concentrated under
reduced pressure to give a residue, which was filtered through a short plug of silica gel (hexanes/EtOAc 8:1 (2% Et3N)
to 1:1 (2% Et3N)) to give a 1:1 mixture of benzylidene acetals 5* (endo) and 6* (exo) (3.46 g, 8.03 mmol, 92%). The
isomers were separated by selective crystallization of exo-isomer 6* from EtOAc/hexanes and chromatographic sepa-
ration of the mother liquor (Biotage, flat gradient of 10% to 40% EtOAc in hexanes + 0.5% Et3N). Analytical data for 5*:
Clear oil. HRMS (ESI) calcd for C23H26O6S (M+Na)+ 453.1348, found 453.1352 m/z. Analytical data for 6*: White solid.
HRMS (ESI) calcd for C23H26O6S (M+Na)+ 453.1348, found 453.1338 m/z.
[0128] Example 6: Methyl (ethyl 2,3-O-benzyl-1-thio-β-D-galactopyranosyl)uronate (7*): To a solution of acetal
6* (162 mg, 0.38 mmol) and sodium cyanoborohydride (296 mg, 4.70 mmol) in THF (9.4 ml) was added at room tem-
perature a solution of hydrogen chloride (1 M in Et2O) until the evolution of gas ceased. After 10 min, sodium cyanoboro-
hydride (296 mg, 4.70 mmol) was added, followed by the addition of HCl. The reaction was stirred at room temperature,
diluted with EtOAc (30 ml) and quenched with sat. aq. NaHCO3 (30 ml). After separation, the organic layer was washed
with sat. aq. NaHCO3 (20 ml) and the aqueous layer was re-extracted with EtOAc (2x20 ml). The organic extracts were
pooled, dried over MgSO4 and concentrated. The residue was purified by flash chromatography (EtOAc/hexanes 1:1)
to give alcohol 7* (67.5 mg, 0.156 mmol, 42%) as a white solid. HRMS (ESI) calcd for C23H28O6S (M+Na+) 455.1504
found 455.1511 m/z.
[0129] Example 7: Methyl (ethyl 2,3-O-benzyl-4-O-fluorenylmethoxycarbonyl-1-thio-β-D-galactopyranosyl)ur-
onate (8*): To a stirring solution of alcohol 7* (160 mg, 0.370 mmol) in pyridine (1.2 ml) was added at 0 °C FmocCl (383
mg, 1.48 mmol). The mixture was warmed to room temperature and stirred for 3 h. The mixture was then diluted with
EtOAc (50 ml) and washed with 1 N HCl (2x30 ml) and sat. aq. NaHCO3 (30 ml). The organic phase was dried over
Na2SO4 and concentrated. The residue was purified by flash chromatography (EtOAc/hexanes 1:2) to give carbonate
8* (217 mg, 0.331 mmol, 90%) as a white foam. HRMS (ESI) calcd for C38H38O8S (M+Na)+ 677.2185 found 677.2167 m/z.
[0130] Example 8: Dibutyl [methyl (2,3-O-benzyl-4-O-fluorenylmethoxycarbonyl-α/β-D-galactopyranosyl)uro-
nate] phosphate (9*): Thioglycoside 8* (200 mg, 0.305 mmol) was co-evaporated with dry toluene (2x30 ml), kept under
high vacuum for 1 h and dissolved in dry CH2Cl2 (3 ml). Activated molecular sieves (3 A-AW) were added and the solution
was stirred for 15 min at room temperature. The solution was then cooled to 0 °C, treated with dibutyl phosphoric acid
(128 mg, 0.611 mmol) and stirred for another 15 min. The mixture was then treated with NIS (89 mg, 0.397 mmol),
warmed to room temperature and stirred for 3 h at that temperature. The reaction was diluted with CH2Cl2 (20 ml) and
quenched with a 1:1 (v/v) mixture of 10% aq. Na2S2O3 and sat. aq. NaHCO3 (20 ml). The aqueous phase was extracted
with CH2Cl2 (3x30 ml), the combined organic fractions were dried over Na2SO4 and concentrated. The residue was
purified by flash chromatography (EtOAc/hexanes 1:1 to 2:1) to give glycosyl phosphate 9* (218 mg, 0.272 mmol, 89%,
10:1 α/β as clear oil. Analytical data of 9*α: HRMS (ESI) calcd for C44H51O12P (M+Na)+ 825.3015 found 825.3020 m/z.
Analytical data of 9*β: HRMS (ESI) calcd for C44H51O12P (M+Na)+ 825.3015 found 825.2970 m/z.
[0131] Example 9: Methyl (2-O-benzyl-3,4-O-endo-benzylidene-α/β-D-galactopyranosyl)uronate-(1→1)-2-(ben-
zylthio)ethanol (10*): Thioglycoside 5* (102 mg, 0.237 mmol), 2-(benzylthio)ethanol 11* (60 mg, 0.355 mmol) and
TTBPy. (117 mg, 0.474 mmol) were co-evaporated with anh. toluene (3x10 ml) and kept under high vacuum for 30 min.
The mixture was dissolved in THF (4.8 ml) and stirred over activated molecular sieves (3 A) for 30 min at room temperature.
The solution was cooled to 0 °C and treated with DMTST (92 mg, 0.355 mmol in 0.2 ml dry CH2Cl2). The reaction was
warmed to room temperature and stirred for 2 h at that temperature. The reaction was quenched with a 1:1 (v/v) Me-
OH/Et3N mixture (0.1 ml) and concentrated. The residue was purified by flash chromatography (EtOAc/hexanes/Et3N
0:1:0.01 to 30:70:0.01 to 45:55:0.01) to give thioether 10*α (59 mg, 0.110 mmol, 46%) as a clear oil, along with the
corresponding β-isomer 10*β (35 mg, 0.065 mmol, 27%). Analytical data for 10*α: HRMS (ESI) calcd for C30H32O7S
(M+Na)+ 559.1766 found 559.1731 m/z.
[0132] Example 10: Methyl (2,4-di-O-benzyl-α-D-galactopyranosid)uronate-(1→1)-2-(benzylthio)ethanol (12*):
To a stirred solution of acetal 10*α (100.0 mg, 0.186 mmol) in dry THF (5.3 ml) was added first borane trimethylamine
complex (57.4 mg, 0.745 mmol) and then aluminium chloride (149 mg, 1.118 mmol) at room temperature. The mixture
was stirred for 4.5 h. The reaction was quenched by addition of water (10 ml) and 1 M aq. HCl (5 ml). The mixture was













extracted with EtOAc (3x 10 ml) and the combined organic fractions were dried over Na2SO4 and concentrated. The
residue was purified by flash chromatography (EtOAc/hexanes 2:5 to 1:1) to give alcohol 12* (70.0 mg, 0.13 mmol, 70%)
as a clear oil. HRMS (ESI) calcd for C30H34O7S (M+Na)+ 561.1923 found 561.1879 m/z.
[0133] Example 11: Methyl (2,3-di-O-benzyl-4-O-fluorenylmethoxycarbonyl-α-D-galactopyranosyl)uro-
nate-(1→3)-methyl (2,4-di-O-benzyl-α-D-galactopyranosyl)uronate-(1→3)-(2-(benzylthio)ethanol (13*): Alcohol
12* (90 mg, 0.166 mmol) and glycosyl phosphate 9* (208 mg, 0.259 mmol) were co-evaporated with dry toluene (3x10
ml) and kept under high vacuum for 1 h. The mixture was dissolved in dry CH2Cl2 (3.3 ml) and stirred over activated
molecular sieves (3 A-AW) for 30 min at room temperature. The solution was cooled to 0 °C and treated dropwise with
TBSOTf (0.133 mmol in 0.2 ml dry CH2Cl2). The solution was warmed to room temperature and stirred for 20 h. The
reaction was diluted with CH2Cl2 (10 ml) and quenched with a 1:1 (v/v) MeOH/pyridine mixture (0.2 ml). The solution
was filtered through Celite and concentrated. The crude product was filtered through a short plug of silica gel (EtOAc/hex-
anes 1:1) to give the intermediate disaccharide mixture (150 mg, 0.133 mmol, 80%, 3:1 α/β) as a clear oil.
To a stirred solution of the carbonate mixture (150 mg) in CH2Cl2 (2.6 ml) was added at room temperature triethylamine
(1.1 ml, 7.96 mmol).The reaction was stirred for 3 h at that temperature and co-evaporated with toluene (2x10 ml). The
residue was purified by flash chromatography (EtOAc/hexanes 1:6 to 2:3 to 1:1) to give alcohol 13* (62 mg, 0.068 mmol,
51 %) along with the corresponding β-anomer (20 mg, 0.022 mmol, 17%). HRMS (ESI) calcd for C51H56O13S (M+Na)+
931.3339, found 931.3340 m/z.
[0134] Example 12: 2-Azido-4-(benzyloxycarbonyl)amino-3-O-levulinoyl-2,4,6-trideoxy-α-D-galactopyrano-
syl-(1→4)-methyl (2,3-di-O-benzyl-α-D-galactopyranosyl)uronate-(1→3)-methyl (2,4-di-O-benzyl-α-D-galacto-
pyranosyl)uronate-(1→1)-2-(benzylthio)ethanol (14*): Alcohol 13* (65 mg, 0.062 mmol) and glycosyl phosphate 2*
(61 mg, 0.100 mmol) were co-evaproated with dry toluene (3x10 ml) and kept under high vacuum for 30 min. The mixture
was dissolved in CH2Cl2 (2.1 ml) and stirred over activated molecular sieves (4 A-AW) for 1 h at room temperature. The
solution was then cooled to 0 °C and treated with TMSOTf (17 ml, 0.093 mmol in 0.2 ml dry CH2Cl2). The mixture was
allowed to stir for 3 h at 0 °C, when TLC (EtOAc/hexanes 2:3) indicated complete consumption of the acceptor. The
reaction was quenched with a 1:1 (v/v) MeOH/NEt3 mixture (0.5 ml), diluted with CH2Cl2 (20 ml) and filtered through
Celite. The crude product was purified by flash chromatography (EtOAc/hexanes 1:2 to 1:1) to give trisaccharide 14*
(69 mg, 0.053 mmol, 85%) as a clear oil. HRMS (ESI) calcd. for C70H78N4O19S (M+Na)+ 1333.4879 found 1333.4911 m/z.
[0135] Example 13: 2-Azido-4-(benzyloxycarbonyl)amino-2,4,6-trideoxy-α-D-galactopyranosyl-(1→4)-methyl
(2,3-di-O-benzyl-α-D-galactopyranosyl)uronate-(1→3)-methyl (2,4-di-O-benzyl-α-D-galactopyranosyl)uro-
nate-(1→1)-2-(benzylthio)ethanol (15*): To a stirred solution of levulinoyl ester 14* (30 mg, 0.023 mmol) in dry CH2Cl2
(1.0 ml) was added at room temperature first a mixture of pyridine (56 ml, 0.692 mmol) and acetic acid (37 ml, 0.646
mmol), and then hydrazine hydrate (2 ml, 0.041 mmol). The mixture was allowed to stir for 4 h at room temperature,
diluted with EtOAc (2 ml), quenched with acetone (0.1 ml) and poured into water (15 ml). The aqueous phase was
extracted with EtOAc (4x10 ml), and the combined organic extracts were dried over Na2SO4 and concentrated under
reduced pressure. The residue was purified by flash chromatography (EtOAc/hexanes 0:1 to 1:2 to 2:3) to give alcohol
15* (28 mg, 0.023 mmol, 100%) as a clear oil. HRMS (ESI) calcd. for C65H72N4O17S (M+Na)+ 1235.4511 found 1235.4539
m/z.
[0136] Example 14: 2-Azido-4-(benzyloxycarbonyl)amino-3-O-benzyloxymethyl-2,4,6-trideoxy-α-D-galacto-
pyranosyl-(1→4)-methyl (2,3-di-O-benzyl-α-D-galactopyranosyl)uronate-(1 →3)-methyl (2,4-di-O-benzyl-α-D-ga-
lactopyranosyl)uronate-(1→1)-2-(benzylthio)ethanol (16*): Alcohol 15* (8.6 mg, 7.1 mmol), benzyloxymethyl thiocy-
clohexane (79 mg, 0.354 mmol) and TTBPy. (105 mg, 0.425 mmol) were coevaproated with dry toluene (3x10 ml) and
kept under high vacuum for 30 min. The mixture was dissolved in dry CH2Cl2 (0.4 ml) and stirred over activated molecular
sieves (3 A) for 30 min at room temperature. The mixture was cooled to 0 °C and DMTST (7.1 mg, 0.18 mmol in 0.1 ml
CH2Cl2) was added dropwise over 45 min, while the reaction temperature was kept below 10 °C. The reaction was
stirred for another 45 min, quenched by addition of a 1:1 (v/v) MeOH/Et3N mixture and concentrated. The residue was
purified by flash chromatography (EtOAc/hexanes 1:10 to 1:2) to give acetal 16* (6.0 mg, 4.5 mmol, 64%) as a clear oil.
HRMS (ESI) calcd for C73H80N4O18S (M+Na)+ 1355.5086 found 1355.5071 m/z.
[0137] Example 15: 2-Acetamido-4-(benzyloxycarbonyl)amino-3-O-benzyloxymethyl-2,4,6-trideoxy-α-D-ga-
lactopyranosyl-(1→4)-methyl (2,3-di-O-benzyl-α-D-galactopyranosyl)uronate-(1 →3)-methyl (2,4-di-O-benzyl-α-
D-galactopyranosyl)uronate-(1→1)-2-(benzylthio)ethanol (17*): To a stirred solution of azide 16* (14.0 mg, 10.5
mmol) in dry pyridine (0.35 ml) was added at 0 °C thioacetic acid (0.35 ml). The mixture was warmed to room temperature
and stirred for 24 h at that temperature. The solution was co-evaporated with toluene (2x5 ml) and the residue was
purified by flash chromatography (EtOAc/hexanes 1:10 to acetone/hexanes 1:7 to 1:5 to 1:3) to give acetamide 17* (9.4
mg, 7.0 mmol, 66%) as a white solid. HRMS (ESI) calcd for C75H84N2O19S (M+Na)+ 1371.5281 found 1371.5314 m/z.
[0138] Example 16: 2,2’-Dithiobis[2-acetamido-4-amino-2,4,6-trideoxy-α-D-galactopyranosyl-(1→4)-α-D-ga-
lactopyranosyluronate-(1→3)-α-D-galactopyranosyluronate-(1→1)-1-ethanol] (18*): To a stirred solution of diester
17* in THF (4.0 ml) and MeOH (0.8 ml) was added at 0 °C a 1 M solution of NaOH in water (1.5 ml). The reaction was
slowly warmed to room temperature and stirred for 16 h. The reaction was diluted with EtOAc (5 ml) and acidified to pH













4 with 0.5 M aq. NaHSO4. After separation, the aqueous fraction was extracted with EtOAc (8x10 ml), the combined
organic fractions were dried over Na2SO4 and concentrated to give the intermediate diacid as a white solid.
To a stirring solution of liquid ammonia (5 ml) was added at -78 °C a solution of the crude diacid in THF (1.5 ml). The
mixture was treated with tBuOH (0.5 ml) and lumps of freshly cut sodium (45 mg) were added until a deeply blue color
persisted. The reaction was stirred at -78 °C for 45 min and quenched by addition of solid ammonium acetate (200 mg).
The solution was warmed to room temperature under a stream of argon and co-evaporated with MeOH (2x10 ml) and
water (2x5 ml). The residue was left under air for 16 h, purified by size exclusion chromatography (Sephadex G-25, 1:1
MeOH/5 mM aq. NH4OAc) and lyophilized repeatedly to give disulfide 18* (1.4 mg, 1.65 mmol, 32%) as a white solid.
HRMS (MALDI) calcd for C44H70N4O32S2 (M-H+) 1229.3330 found 1229.3342 m/z.
[0139] Example 17: Methyl (ethyl 2,3-O-benzyl-4-O-levulinoyl-1-thio-β-D-galactopyranosyl)uronate (19*): To a
stirred solution of alcohol 7* (94 mg, 0.217 mmol) in CH2Cl2 (1.9 mL) were added at room temperature levulinic acid
(386 mg, 3.26 mmol), DCC (673 mg, 3.26 mmol) and pyridine (0.26 mL, 3.26 mmol). The mixture was stirred at that
temperature for 35 h, diluted with CH2Cl2 (5 mL) and filtered through Celite. The mixture was concentrated, the residue
was dissolved in a minimal volume of CH2Cl2 (1-3 mL) and filtered through cotton wool. The same procedure was
repeated 3 times. The residue was purified by flash chromatography (EtOAc/toluene 1:1) to give ester 19* (91 mg, 0.171
mmol, 79%) as a slightly yellow oil. HRMS (ESI) calcd for C28H34O8S (M+Na)+ 553.1872 found 553.1872 m/z.
[0140] Example 18: Methyl (2,3-di-O-benzyl-α-D-galactopyranosid)uronate-(1→1)-6-(benzylthio)hexanol (20*):
Thioglycoside 19* (87 mg, 0.164 mmol), 6-(benzylthio)hexanol 21* (85 mg, 0.379 mmol) and TTBPy. (97 mg, 0.392
mmol) were co-evaporated with anh. toluene (3x10 ml) and kept under high vacuum for 30 min. The mixture was dissolved
in Et2O (2.5 ml) and CH2Cl2 (0.83 ml) and stirred over activated molecular sieves (3 A) for 30 min at room temperature.
The solution was cooled to 0 °C and treated with DMTST (63.5 mg, 0.246 mmol). The reaction was warmed to room
temperature and stirred for 8 h at that temperature. The reaction was quenched with a 1:1 (v/v) mixture of MeOH and
triethylamine (0.1 ml) and concentrated. The residue was purified by flash chromatography (EtOAc/CH2Cl2/hexanes
0:0:1 to 1:2:1) to give the corresponding glycosides (60 mg) as an inseparable α/β mixture.
To a stirred solution of the glycoside mixture in dry CH2Cl2 (2.2 ml) were added at room temperature first a mixture of
pyridine (195 ml, 2.411 mmol) and acetic acid (137 ml, 2.393 mmol), and then hydrazine hydrate (5.9 ml, 0.121 mmol).
The mixture was stirred for 2 h at that temperature, diluted with EtOAc (2 ml), quenched with acetone (0.1 ml) and poured
into water (15 ml). The aqueous phase was extracted with EtOAc (4x10 ml), the combined organic extracts were dried
over Na2SO4 and concentrated. The residue was purified by flash chromatography (EtOAc/hexanes 1:2) to give alcohol
20* (29 mg, 0.049 mmol, 30% over two steps) as a clear oil, along with the corresponding β-isomer (22 mg, 0.037 mmol,
22%). HRMS (ESI) calcd. for C34H42O7S (M+Na)+ 617.2544 found 617.2542 m/z.
[0141] Example 19: 6,6’-Dithiobis[α-D-galactopyranosyluronate-(1→1)-1-hexanol] (22*): To a stirred solution of
ester 20* (10 mg, 0.017 mmol) in THF (1.0 ml) and MeOH (0.5 ml) was added at 0 °C a 1 M solution of NaOH in water
(0.8 ml). The reaction was slowly warmed to room temperature and stirred for 16 h. The reaction was diluted with EtOAc
(5 ml) and water (5 ml) and acidified to pH 4 with 0.5 M aq. NaHSO4. After separation, the aqueous fraction was extracted
with EtOAc (8x5 ml), the combined organic fractions were dried over Na2SO4 and concentrated to give the intermediate
acid as a white solid.
To a stirred solution of liquid ammonia (8 ml) was added at -78 °C a solution of the crude diacid in THF (2 ml). The
mixture was treated with tBuOH (0.4 ml) and lumps of freshly cut sodium (45 mg) were added until a deeply blue color
persisted. The reaction was stirred at -78 °C for 45 min and quenched by addition of solid ammonium acetate (100 mg).
The solution was warmed to room temperature under a stream of argon and co-evaporated with MeOH (2x10 ml) and
water (2x5 ml). The residue was left under air for 16 h, purified by size exclusion chromatography (Sephadex G-25, 9:1
MeOH/5 mM aq. NH4OAc) and lyophilized repeatedly to give disulfide 22* (3.1 mg, 5.1 mmol, 60% over two steps) as
a white solid. HRMS (MALDI) calcd for C24H42O14S2 (M-H+) 617.1938 found 617.1954 m/z.
[0142] Example 20: 2-Acetamido-4-(benzyloxycarbonyl)amino-3-O-levulinoyl-2,4,6-trideoxy-α-D-galacto-
pyranosyl-(1→1)-6-(benzylthio)hexanol (23*): 6-(Benzylthio)hexanol 21* (29 mg, 0.171 mmol) and glycosyl phosphate
2* (70 mg, 0.114 mmol) were co-evaproated with dry toluene (3x10 ml) and kept under high vacuum for 30 min. The
mixture was dissolved in CH2Cl2 (1.8 ml) and stirred over activated molecular sieves (4 A-AW) for 1 h at room temperature.
The solution was then cooled to 0 °C and treated with TMSOTf (31 ml, 0.171 mmol in 0.2 ml dry CH2Cl2). The mixture
was stirred for 3 h at that temperature, quenched with a 1:1 (v/v) mixture of MeOH and triethylamine (0.5 ml), diluted
with CH2Cl2 (20 ml) and filtered through Celite. The residue was purified by flash chromatography (EtOAc/hexanes 2:3
to 3:2) to give the corresponding glycosides (57 mg) as an inseparable α/β mixture.
To a stirred solution of the glycoside mixture in dry pyridine (0.9 ml) was added at 0 °C thioacetic acid (0.9 ml). The
mixture was warmed to room temperature and stirred for 24 h at that temperature. The solution was co-evaporated with
toluene (2x5 ml) and the residue was purified by flash chromatography (EtOAc/hexanes 1:2 to 2:1 to 6:1) to give acetamide
23* (22 mg, 0.034 mmol, 29% over two steps) as a white solid, along with the corresponding β-isomer (21.6 mg, 0.034
mmol, 29%). HRMS (ESI) calcd for C34H46N2O8S (M+Na)+ 665.2872 found 665.2865 m/z.
[0143] Example 21: 6,6’-Dithiobis[2-acetamido-4-amino-2,4,6-trideoxy-α-D-galactopyranosyl-(1→1)-1-hexa-













nol] (24*): To a stirred solution of ester 23* (10 mg, 0.016 mmol) in dry CH2Cl2 (1.0 ml) were added at room temperature
first a mixture of pyridine (38 ml, 0.467 mmol) and acetic acid (24.9 ml, 0.436 mmol), and then hydrazine hydrate (1.0
ml, 0.020 mmol). The mixture was stirred for 2 h at that temperature, quenched with acetone (0.1 ml) and purified by
size exclusion chromatography (Sephadex LH-20, CH2Cl2/MeOH 2:1) to give the corresponding alcohol as a clear oil.
To a stirred solution of liquid ammonia (5 ml) was added at -78 °C a solution of the intermediate alcohol in THF (1.2 ml).
The mixture was treated with tBuOH (0.5 ml) and lumps of freshly cut sodium (80 mg) were added until a deeply blue
color persisted. The reaction was stirred at -78 °C for 45 min and quenched by addition of solid ammonium acetate (100
mg). The solution was warmed to room temperature under a stream of argon and co-evaporated with MeOH (2x10 ml)
and water (2x5 ml). The residue was left under air for 16 h, purified by size exclusion chromatography (Sephadex G-
25, 9:1 MeOH/5 mM aq. NH4OAc) and lyophilized repeatedly to give disulfide 24* (1.7 mg, 2.7 mmol, 33% over two
steps) as a white solid. HRMS (ESI) calcd. for C28H54N4O8S2 (M+Na)+ 661.3281 found 661.3306 m/z.
[0144] Example 22: 2-Acetamido-4-(benzyloxycarbonyl)amino-3-O-levulinoyl-2,4,6-trideoxy-α-D-galacto-
pyranosyl-(1→1)-2-(benzylthio)ethanol (25*): 2-(benzylthio)ethanol 11* (71 mg, 0.421 mmol) and glycosyl phosphate
2* (171 mg, 0.281 mmol) were co-evaproated with dry toluene (3x10 ml) and kept under high vacuum for 30 min. The
mixture was dissolved in CH2Cl2 (1.8 ml) and stirred over activated molecular sieves (4 A-AW) for 1 h at room temperature.
The solution was then cooled to -40 °C and treated with TMSOTf (56 ml, 0.309 mmol in 0.2 ml dry CH2Cl2). The mixture
was slowly warmed to 0 °C (2 h), quenched with a 1:1 (v/v) mixture of MeOH and triethylamine (0.5 ml), diluted with
CH2Cl2 (20 ml), filtered through Celite and concentrated. The residue was purified by flash chromatography (EtOAc/hex-
anes 1:3 to 1:1) to give the corresponding α-glycoside (55 mg, 0.096 mmol, 34%) along with the corresponding β-
glycoside (22 mg, 0.039 mmol, 14%). To a stirred solution of the intermediate α-glycoside (40 mg, 0.070 mmol) in dry
pyridine (0.4 ml) was added at 0 °C thioacetic acid (0.4 ml). The mixture was warmed to room temperature and stirred
for 24 h at that temperature. The solution was co-evaporated with toluene (2x5 ml) and the residue was purified by flash
chromatography (EtOAc/hexanes 1:3 to acetone/hexanes 1:2 to 2:3) to give acetamide 25* (31 mg, 0.053 mmol, 76%)
as a white solid. HRMS (ESI) calcd for C3oH38N2O8S (M+Na)+ 609.2246 found 609.2256 m/z.
[0145] Example 23: 6,6’-Dithiobis[2-acetamido-4-amino-2,4,6-trideoxy-α-D-galactopyranosyl-(1→1)-1-hexa-
nol] (26*): To a stirred solution of ester 25* (20.7 mg, 0.035 mmol) in dry CH2Cl2 (3.0 ml) were added at room temperature
first a mixture of pyridine (86 ml, 1.058 mmol) and acetic acid (57 ml, 0.988 mmol), and then hydrazine hydrate (3.4 ml,
0.071 mmol). The mixture was stirred for 5 h at that temperature, diluted with EtOAc (2 ml), quenched with acetone (0.1
ml) and poured into water (10 ml). The aqueous phase was extracted with EtOAc (4x5 ml), the combined organic fractions
were dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (acetone/hexanes 1:1)
to give the intermediate alcohol (17.5 mg) as a white solid.
To a stirred solution of liquid ammonia (6 ml) was added at -78 °C a solution of the intermediate alcohol in THF (1.5 ml).
The mixture was treated with tBuOH (0.5 ml) and lumps of freshly cut sodium (45 mg) were added until a deeply blue
color persisted. The reaction was stirred at -78 °C for 45 min and quenched by addition of solid ammonium acetate (100
mg). The solution was warmed to room temperature under a stream of argon and co-evaporated with MeOH (2x10 ml)
and water (2x5 ml). The residue was left under air for 16 h, purified by size exclusion chromatography (Sephadex G-
25, 1:10 MeOH/5 mM aq. NH4OAc) and lyophilized repeatedly to give disulfide 26* as the diacetate salt (7.91 mg, 12.3
mmol, 70% over two steps) as a white solid. HRMS (ESI) calcd. for C20H38N4O8S2 (M+Na)+ 549.2029 found 549.2086 m/z.
[0146] Example 24: 2,2’-Dithiobis[α-D-galactopyranosyluronate-(1→3)-α-D-galactopyranosyluronate-(1→1)-1-
ethanol] (27*): To a stirred solution of ester 13* (8.6 mg, 9.5 mmol) in THF (0.6 ml) and MeOH (0.3 ml) was added at 0
°C a 1 M solution of NaOH in water (0.5 ml). The reaction was slowly warmed to room temperature and stirred for 16 h.
The reaction was diluted with EtOAc (5 ml) and water (5 ml) and acidified to pH 4 with 0.5 M aq. NaHSO4. After separation,
the aqueous fraction was extracted with EtOAc (8x5 ml), the combined organic fractions were dried over Na2SO4 and
concentrated to give the intermediate diacid as a white solid.
To a stirred solution of liquid ammonia (6 ml) was added at -78 °C a solution of the crude diacid in THF (1.5 ml). The
mixture was treated with tBuOH (0.4 ml) and lumps of freshly cut sodium (75 mg) were added until a deeply blue color
persisted. The reaction was stirred at -78 °C for 45 min and quenched by addition of solid ammonium acetate (100 mg).
The solution was warmed to room temperature under a stream of argon and co-evaporated with MeOH (2x10 ml) and
water (2x5 ml). The residue was left under air for 16 h, purified by size exclusion chromatography (Sephadex G-25, 1:9
MeOH/5 mM aq. NH4OAc) and lyophilized repeatedly to give disulfide 27* (2.5 mg, 2.9 mmol, 61 % over two steps) as
a white solid. HRMS (MALDI) calcd for C28H42O26S2 (M-H+) 901.0966 found 901.0981 m/z.
Synthesis of glycoconjugates
[0147] Example 25: Conjugation of saccharides of general formula (I) to CRM197: To a stirred solution of CRM197
(1 mg, 17.2 nmol) in 0.1 M sodium phosphate buffer (NaPi) pH 7.4 (1 ml) was added at room temperature a solution of
succinimidyl-3-(bromoacetamido)propionate (SBAP) (264 mg, 863 nmol) in DMF (20 ml). The mixture was stirred for 1
h at that temperature, and concentrated using membrane filtration (Amicon Ultra centrifuge membranes, 10 kDa cut-













off). The protein solution was diluted with 0.1 M NaPi pH 7.4 and concentrated again. This process was repeated three
times and the solution was diluted to 1 ml using 0.1 M NaPi pH 7.4. The intermediate of general formula (II) (690 mmol)
in 120 ml 0.1 M NaPi pH 7.4 was treated at room temperature with tris(2-carboxyethyl)phosphine (TCEP) (690 mmol),
left for 1 h at that temperature under an argon atmosphere and added to the solution of the bromoacetamido-modified
CRM197 protein at room temperature. The mixture was left at room temperature for 2 h and then at 4 °C for 16 h, and
purified using membrane filtration (see above). The purified glycoconjugate in 0.1 M NaPi pH 7.4 (1 ml) was then treated
at room temperature with L-cysteine (417 mg, 3.45 mmol) in 100 ml water. The mixture was left for 2 h at that temperature
and purified by membrane filtration. Incorporation of the saccharide of general formula (I) into the glycoconjugate was
assessed by MALDI-TOF-MS, SDS-PAGE and size exclusion chromatography with right angle light scattering detection
(SEC-RALS).
Example 26: In flow conjugation of the saccharides of general formula (I) to a glycosphingolipid with immu-
nomodulatory properties
[0148] By using a photochemical flow reactor (Chem. Eur. J. 2013, 19, 3090) that was fitted with a loop of Teflon
AF2400 tubing (566 mL), a solution of saccharide of general formula (I) (1.5 equiv.) in water (300 mL) was reacted with
pentenyl modified (2S,3S,4R)-1-(α-D-galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol (1 equiv.) in water
(300 mL) and AcOH (8 mL; residence time: 10 min, flow rate: 28.3 mL/min-1 per syringe). The reactor output was lyophilized
and the crude material was purified using size exclusion chromatography (Sephadex-G25, 5% EtOH in water, 10 mmx150
mm) to yield the glycoconjugate of saccharide of general formula (I) covalently linked to the modified (2S,3S,4R)-1-(α-
D-galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol as white solid.
Example 27: Conjugation of 2-acetamido-4-amino-2,4,6-trideoxy-α-D-galactopyranosyl-(1→4)-(α-D-galacto-
pyranosyl)uronate-(1→3)-(α-D-galactopyranosyl)uronate-(1→1)-2-(thio)ethanol to BSA
[0149] To a stirred solution of BSA (0.5 mg, 7.6 nmol) in 0.1 M sodium phosphate buffer (NaPi) pH 7.4 (1 mL) was
added at room temperature a solution of N-succinimidyl-3-(bromoacetamido)propionate (SBAP) (89 mg, 290 nmol) in
DMF (20 mL). The mixture was stirred for 1 h at room temperature, and concentrated using membrane filtration (Amicon
0.5 mL Ultra centrifuge membranes, 10 kDa cut-off). The protein solution was diluted with 0.1 M NaPi pH 7.4 and
concentrated again. This process was repeated three times and the solution was diluted to 0.5 mL using water. 20 mL
were taken for analysis, and the protein solution was re-buffered to 0.1 M NaPi pH 7.4 using membrane filtration. Disulfide
18* (140 mg, 228 nmol resp. to the monomer) in 120 mL 0.1 M NaPi pH 7.4 was treated at room temperature with tris(2-
carboxyethyl)phosphine (TCEP) (250 nmol), left for 1 h at that temperature under an argon atmosphere and added to
the solution of the activated protein at room temperature. The mixture was left at 4 °C for 16 h, and purified using
membrane filtration (see above). After washing with water and diluting to 0.5 mL, another analytical sample (20 mL) was
taken, and the solution was re-buffered. The purified glycoconjugate in 0.1 M NaPi pH 7.4 (0.5 mL) was then treated at
room temperature with L-cysteine (417 mg, 3.45 mmol) in 100 ml water. The mixture was left for 2 h at that temperature
and purified by membrane filtration. Incorporation of 2-acetamido-4-amino-2,4,6-trideoxy-α-D-galactopyrano-
syl-(1→4)-(α-D-galactopyranosyl)uronate-(1→3)-(α-D-galactopyranosyl)uronate-(1→1)-2-(thio)ethanol into the glyco-
conjugate was assessed by MALDI-TOF-MS (positive mode):
Molecular weight measured:
BSA: 66341 m/z.
BSA-SBAP conjugate: 68316 m/z (incorporation of approximately 10 SBAP groups).
BSA-SBAP glycoconjugate: 69101 m/z (incorporation of approximately 1.3 molecules of 2-acetamido-4-amino-
2,4,6-trideoxy-α-D-galactopyranosyl-(1→4)-(α-D-galactopyranosyl)uronate-(1→3)-(α-D-galactopyranosyl)ur-
onate-(1→1)-2-(thio)ethanol).
BSA-SBAP glycoconjugate after quenching with L-cysteine: 72074 m/z (incorporation of approx. 24.5 L-cysteine
molecules).
Example 28: Conjugation of 2-acetamido-4-amino-2,4,6-trideoxy-α-D-galactopyranosyl-(1→4)-(α-D-galacto-
pyranosyl)uronate-(1→3)-(α-D-galactopyranosyl)uronate-(1→1)-2-(thio)ethanol to BSA
[0150] To a stirred solution of BSA (0.5 mg, 7.6 nmol) in 0.1 M sodium phosphate buffer (NaPi) pH 7.4 (1 mL), a
solution of N-Succinimidyl-3-maleimidopropionate (101 mg, 380 nmol) in DMF (20 mL) was added at room temperature.
The mixture was stirred for 1 h at room temperature, and concentrated using membrane filtration (Amicon 0.5 mL Ultra
centrifuge membranes, 10 kDa cut-off). The protein solution was diluted with 0.1 M NaPi pH 7.4 and concentrated again.













This process was repeated three times and the solution was diluted to 0.5 mL using water. 20 mL were taken for analysis,
and the protein solution was re-buffered to 0.1 M NaPi pH 7.4 using membrane filtration. Disulfide 18* (140 mg, 228
nmol resp. to the monomer) in 120 ml 0.1 M NaPi pH 7.4 was treated at room temperature with tris(2-carboxyethyl)phos-
phine (TCEP) (250 nmol), left for 1 h at that temperature under an argon atmosphere and added to the solution of the
activated protein at room temperature. The mixture was left at 4 °C for 16 h, and purified using membrane filtration (see
above). After washing with water and diluting to 0.5 mL, another analytical sample (20 mL) was taken, and the solution
was re-buffered. The purified glycoconjugate in 0.1 M NaPi pH 7.4 (0.5 mL) was then treated at room temperature with
L-cysteine (417 mg, 3.45 mmol) in 100 ml water. The mixture was left for 2 h at that temperature and purified by membrane
filtration. Incorporation of glycan into the glycoconjugate was assessed by MALDI-TOF-MS (positive mode):
Molecular weight measured:
BSA: 66341 m/z;
BSA-maleimide conjugate: 69254 m/z (incorporation of approximately 19 maleimide groups);
BSA-maleimide glycoconjugate: 71340 m/z (incorporation of approximately 3.4 molecules of 2-acetamido-4-
amino-2,4,6-trideoxy-α-D-galactopyranosyl-(1→4)-(α-D-galactopyranosyl)uronate-(1→3)-(α-D-galacto-
pyranosyl)uronate-(1→1)-2-(thio)ethanol);
BSA-maleimide glycoconjugate after quenching with L-cysteine: 72106 m/z (incorporation of approx. 6.3 L-
cysteine molecules).
Conjugation to a solid support: synthesis of microarrays coated with saccharides of general formula (I)
Example 29: Synthesis of microarrays using GAPSII slides
[0151] Maleimide-functionalized microarrays were produced by submerging amine-coated slides (GAPS II slides,
Corning) in 6-maleimidohexanoic acid N-hydroxysuccinimide ester (2 mM) in dry DMF with diisopropylethylamine (2.5%
v/v) for 24 h at room temperature. Slides were washed three times with water and three times with ethanol, centrifuged
to dryness, and stored under argon until spotting. Diluted saccharides of general formula (I) were printed onto the modified
microarray slides at 0.4 nL per spot by an automatic piezoelectric arraying robot (Scienion, Berlin, Germany). For
completion of the immobilization reaction, printed slides were stored for 24 h in a humidified chamber.
[0152] Microarray slides were washed three times with water. Unreacted maleimide was quenched by submerging
the slides in β-mercaptoethanol (0.1%, v/v) in PBS for 1 h at room temperature. Slides were washed three times with
water and with ethanol, centrifuged to dryness, and blocked with BSA (1%, w/v) in PBS for 1 h at room temperature.
Blocked slides were washed (2x PBS, 3 x water), centrifuged, and incubated with the sera dilutions.
Example 30: Synthesis of microarrays using CodeLink NHS slides
[0153] CodeLink NHS slides were incubated for 24 h (1% w/v in PBS) at 4 °C. Slides were incubated in blocking buffer
(100 mM ethanolamine in 50 mM NaPi pH > 9) for 30 min at room temperature, washed three times each with water
and ethanol, and dried. Slides were then subjected to maleimide functionalization and printing (see Example 29).
Example 31: Binding experiments using the microarrays synthesized according to the procedure described at 
examples 29 and 30.
[0154] Binding experiments were performed by incubating microarray slides coated with the saccharides of general
formula (I) with either a rabbit anti-SP1 typing serum or human pneumococcal reference serum 007sp (pooled sera of
287 humans immunized with Pneumovax vaccine) in the dilutions indicated in the presence or absence of native SP1
polysaccharide, and using fluorescently labeled anti-rabbit or anti-human secondary antibodies.
Claims
1. Saccharide of general formula (I):













wherein A is a linker;
M, N and P represent independently of each other one of the following sugar fragments:
wherein each moiety S1, S2, and S3 is not more than once present in the general formula (I) sugar fragment S1
cannot be simultaneously bound to -O-A-SH and sugar fragment S2, sugar fragment S3 cannot be simultaneously
bound to -O-A-SH and sugar fragment S1 and sugar fragment S2 cannot be simultaneously bound to -O-A-SH and
sugar fragment S3 and
n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
and pharmaceutically acceptable salts of these saccharides.
2. Synthesis of the saccharide of the general formula (I):
wherein A is a linker;
M, N and P represent independently of each other one of the following sugar fragments:
wherein each moiety S1, S2, and S3 is not more than once present in the general formula (I), sugar fragment S1
cannot be simultaneously bound to -O-A-SH and sugar fragment S2, sugar fragment S3 cannot be simultaneously
bound to -O-A-SH and sugar fragment S1 and sugar fragment S2 cannot be simultaneously bound to -O-A-SH and
sugar fragment S3, and
n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
comprising the steps:













A1) Reacting the compound 2 of the formula:
wherein P1 - P3 represent protecting groups, with the compound 3 of the formula
wherein P4 represents a protecting group, in order to obtain compound 4 of general formula:
wherein P1-P4 and A are defined as above;
and
performing removal of protecting groups P1-P4 on compound 4 to afford monosaccharide disulfide 5 of general
formula:













wherein A is defined as above, and wherein monosaccharide disulfide 5 is further treated with a reducing agent
to afford monosaccharide 6 of general formula:
wherein A is defined as above;
or
performing selective deprotection on compound 4 to afford compound 7 of general formula
wherein P5 is a protecting group and P1, P3, P4 and A are defined as above. or
A2) Reacting compound 8 of general formula
wherein P6 and P7 represent protecting groups, with compound 3 to afford compound 9 of general formula













wherein P6, P7 and A are defined as above;
and
performing conversion of the azido group to acetamide and removal of the protecting groups P4, P6 and P7 on
compound 9 to afford monosaccharide disulfide 10 of general formula:
wherein A is defined as above and, wherein monosaccharide disulfide 10 is further treated with a reducing agent
to afford monosaccharide 11 of general formula:
wherein A is defined as above;
or
performing selective deprotection on compound 9 to afford compound 12 of general formula:













wherein P4, P7 and A are defined as above.
or
A3) Reacting compound 13 of general formula
wherein P8 - P11 represent protecting groups, with compound 3 to afford compound 14 of general formula:
wherein P4, P8 - P11 are defined as above
and
performing selective deprotection of compound 14 to afford compound 15 of general formula:













wherein P4, P8, P9, P11 and A are defined as above.
and
B1) Reacting compound 7 with compound 13 to afford compound 16 of general formula:
wherein P1, P3-P5, P8-P11 and A are defined as above;
and
performing removal of protecting groups P1, P3-P5, P8-P11 on compound 16 to afford disaccharide disulfide 17
of general formula:













wherein A is defined as above and wherein disaccharide disulfide 17 is further treated with a reducing agent to
afford disaccharide 18 of general formula:
wherein A is defined as above;
or
performing selective removal of protecting group P10 on compound 16 to afford compound 19 of general formula:













wherein P1, P3-P5, P8, P9, P11 and A are defined as above.
or
B2) Reacting compound 15 with compound 8 to afford compound 20 of general formula:
wherein P4, P6-P9, P11 and A are defined as above
and
performing conversion of the azido group to acetamide and removal of the protecting groups P4, P6-P9, P11 on
compound 20 to afford disaccharide disulfide 21 of general formula:













wherein A is defined as above and wherein disaccharide disulfide 21 is treated with a reducing agent to afford
disaccharide 22 of general formula:
wherein A is defined as above;
or
performing selective removal of protecting group P6 on compound 20 to afford compound 23 of general formula:













wherein P4, P7-P9, P11 and A are defined as above;
or
B3) Reacting compound 12 with compound 2 to afford compound 24 of general formula:
wherein P1-P4, P7 and A are defined as above,
and
performing conversion of the azido group to acetamide and removal of protecting groups P1-P4 and P7 on
compound 24 to afford disaccharide disulfide 25 of general formula:













wherein A is defined as above, and wherein disaccharide disulfide 25 is further treated with a reducing agent
to afford disaccharide 26 of general formula:
wherein A is defined as above;
or
performing selective deprotection on compound 24 to afford compound 27 of general formula:













wherein P12 is a protecting group and P1, P3, P4, P7 and A are defined as above. and
C1) Reacting compound 19 with compound 8 to afford compound 28 of general formula:
wherein P1, P3-P9, P11 and A are defined as above;
and
wherein protecting group P6 is replaced with protecting group P13 in order to obtain compound 29 of the following
chemical formula:













wherein P1, P3-P5, P7-P9, P11, P13 and A are defined as above;
and
conversion of compound 29 to trisaccharide disulfide 30 by conversion of the azide group in the acetamide
group and cleavage of the protecting group P1, P3-P5, P7-P9, P11, P13, wherein compound 30 is of general
formula:













and wherein A is defined as above;
and
conversion of trisaccharide disulfide 30 to trisaccharide 31 by treatment with a reducing agent, wherein compound
31 is of general formula:
and wherein A is defined as above.
or
C2) Reacting compound 23 with compound 2 to afford compound 32 of general formula:













wherein P1 - P4, P7 - P9, P11 and A are defined as above;
and
conversion of compound 32 to trisaccharide disulfide 33 by conversion of the azide group in the acetamide
group and cleavage of the protecting group P1 - P4, P7 - P9, P11, wherein compound 33 is of general formula:
wherein A is defined as above;
and
conversion of trisaccharide disulfide 33 to trisaccharide 34 by treatment with a reducing agent, wherein compound
34 is of general formula:













wherein A is defined as above;
or
C3) Reacting compound 27 with compound 13 to afford compound 34 of general formula:
wherein P1, P3, P4, P7-P11 and A are defined as above;
and
conversion of compound 35 to trisaccharide disulfide 36 by conversion of the azide group in the acetamide
group and cleavage of the protecting group P1, P3, P4, P7-P11, wherein compound 36 is of general formula:













wherein A is defined as above;
and
conversion of trisaccharide disulfide 36 to trisaccharide 37 by treatment with a reducing agent, wherein compound
37 is of general formula:
wherein A is defined as above.
3. Synthesis according to claim 2 further comprising step D:
D) preparing a salt of the compound of general formula (I) or preparing lyophilisate of the compound of general
formula (I) or of the salt of the compound of general formula (I).













4. Synthesis according to claim 2, wherein the reactions between compounds 2 and 3, compounds 2 and 12, and
compounds 2 and 23 are performed in tetrahydrofurane in presence of DMTST and TTBPy.
5. Synthesis according to claim 2, wherein the replacement of protecting group P6 on compound 28 with protecting
group P13 to obtain compound 29 is performed in two steps, first involving the reaction of compound 28 with hydrazine
or a hydrazinium salt in a mixture of polar and apolar solvents and second by treatment of the product obtained
after the first step with BnOCH2SCy, DMTST and TTBPy in an apolar solvent.
6. Synthesis according to claim 2, wherein the cleavage of the protecting groups involves first cleavage of the base-
labile protecting groups by treatment with a base in a mixture of polar aprotic solvent and a polar protic solvent; and
second cleavage of the protecting groups sensitive to hydrogenation by exposure to sodium and ammonia in a
mixture of polar protic solvents.
7. Intermediate of the general formula (II):
wherein A is a linker;
M, N and P represent independently of each other one of the following fragments:
wherein each moiety S1, S2, and S3 is not more than once present in the general formula (II), sugar fragment S1
cannot be simultaneously bound to -O-A-S- and sugar fragment S2, sugar fragment S3 cannot be simultaneously
bound to -O-A-S- and sugar fragment S1 and sugar fragment S2 cannot be simultaneously bound to -O-A-S-and
sugar fragment S3, and
n1, n2 and n3 are integers selected from 0 and 1
wherein at least one of the integers n1, n2 and n3 is 1 and
and pharmaceutically acceptable salts of these saccharides.
8. Glycoconjugate obtained by reacting the saccharides of general formula (I) with an immunogenic carrier.
9. Glycoconjugate according to claim 8 useful as a vaccine for immunization against diseases associated with bacteria


















10. Glycoconjugate according to claim 9, wherein the bacteria is Streptoccocus pneumoniae serotype 1.
11. Glycoconjugate according to claim 9, wherein the diseases associated with bacteria include pneumonia, meningitis,
otitis media, bacteremia and acute exacerbation of chronic bronchitis, sinusitis, arthritis and conjunctivitis.
12. Pharmaceutical composition comprising the glycoconjugate according to claim 8 and/or the saccharide according
to claim 1 and/or the intermediate according to claim 7 together with at least one pharmaceutically acceptable
cryoprotectant, lyoprotectant, excipient and/or diluent.
13. Pharmaceutical composition according to claim 12, for immunization against diseases associated with Streptococcus
pneumoniae bacteria.
14. Pharmaceutical composition according to claim 13, wherein the Streptococcus pneumoniae bacteria is selected
from the group containing or consisting of Streptococcus pneumoniae type 4, Streptococcus pneumoniae type 9V,
Streptococcus pneumoniae type 2, Streptococcus pneumoniae type 19F, Streptococcus pneumoniae type 3, Strep-
tococcus pneumoniae type 19A, Streptococcus pneumoniae type 12F, Streptococcus pneumoniae type 31, Strep-
tococcus pneumoniae type 7F, Streptococcus pneumoniae type 5, Streptococcus pneumoniae type 14, Streptococ-
cus pneumoniae type 6A, Streptococcus pneumoniae type 6B, Streptococcus pneumoniae type 18C and Strepto-
coccus pneumoniae type 23F.
15. Use of the saccharide according to claim 1 and/or the intermediate according to claim 7 as a marker in immunological
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